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ABSTRACT
Through advances in radiation delivery systems and image guidance, the
accuracy and precision of radiation therapy has improved in recent times. Some
aspects with respect to the accuracy and precision with which treatments are
prescribed and planned have also improved, however it has not been to the
same extent. Radiotherapy has moved from 2D to 3D treatment planning and
now incorporates multimodality imaging into the contouring process, but there
is still variation in tumour delineation. This thesis is an investigation into the
impact of contouring, planning, and organ motion variation on dosimetry and
modelled outcome in a variety of disease scenarios. The effect of contouring
uncertainty in the lung was investigated with a retrospective dataset of nonsmall cell lung cancer patients. Planning uncertainty due to planner experience
was studied using a head and neck case and the influence of organ motion was
considered in the post-prostatectomy setting. Finally, the techniques developed
to analyse contouring variation were applied to a gynaecological clinical trial
benchmarking dataset to incorporate contouring uncertainty into the trial
sample size calculation.

For some treatment sites, the uncertainty in radiotherapy target delineation is
greater than that of organ motion and setup error. As radiotherapy treatment
techniques have become more conformal, the relative importance of contouring
uncertainty has increased compared to other sources of error in the treatment
chain. Understanding the impact of contouring variation on modelled outcome
would aid in the development of contouring guidelines, adaptive radiotherapy
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protocols, margin definition and clinical trial quality assurance. The impact of
contouring variation on modelled outcome was assessed for a series of nonsmall cell lung cancer patients. The results of this work should inform the choice
of metric used and ensure that future contouring studies are more consistent
and comparable.

A significant advantage of IMRT over standard conformal techniques is the
ability to highly conform the dose distribution around sensitive healthy tissues.
This increased conformity comes at the expense of increased plan complexity
and delivery time. In the context of clinical trials, variation in treatment
planning approaches, and the experience of centres in IMRT planning, has been
shown to result in significant variations in dosimetry. There are a variety of
techniques available for producing an IMRT plan and planner experience may
have an impact on the final plan quality. The influence of planner experience on
IMRT plan quality was assessed through a head and neck case planning study.
Treatment delivery time and monitor units ranged from 15-25 minutes and
approximately 800-1200 MU with delivery time increasing with decreasing
planner experience. The planner with the least experience had the poorest plan,
as indicated by achieving the fewest PTV constraints of all planners studied.

It has been known for some time that the prostate bed can experience inter- and
intra-fraction motion due to its proximity to the bladder and bowel, organs that
are constantly filling and emptying. Endorectal balloons (ERBs) have been used
in prostate radiotherapy as organ stabilising devices. In this work, ERBs in the
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post prostatectomy setting were evaluated. The ERB significantly improved
inter-fraction reproducibility for the rectum and the CTV. Concordance indices
for non-ERB and ERB of 0.50 ± 0.12/0.71 ± 0.07 for the rectum and 0.72 ±
0.15/0.73 ± 0.11 for the CTV were demonstrated. However, the improved
geometric stability with the ERB did not translate into a statistically significant
benefit in inter-fraction dosimetric stability.

Protocol deviations in Randomised Controlled Trials have been found to result
in a significant decrease in outcomes. In some cases, the magnitude of the
detrimental effect can be larger than the anticipated benefits of the
interventions involved. The accuracy of radiotherapy contouring is one of
largest contributors to protocol deviations in radiotherapy trials. It is well
recognised that robust methodology and quality assurance is required to ensure
the validity of RCTs. This study aims to model the effect of contouring variation
on tumour control probability (TCP) and consequently on clinical trial sample
size. PORTEC3 is a phase III clinical trial comparing concurrent chemoradiation
and adjuvant chemoradiotherapy with pelvic radiation alone in high risk
advanced stage endometrial carcinoma. A benchmarking exercise was
performed for the PORTEC3 RCT amongst Australian and New Zealand centres.
The results of this benchmarking exercise were then used to assess the
robustness of the sample size calculations. This work provides a framework to
incorporate quantified uncertainties as part of routine benchmarking exercises
in RCT sample size calculations to ensure robust results are obtained from
RCTs.
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Chapter 1: Introduction
“It is best to prove things by actual experiment; then you know; whereas if you
depend on guessing and supposing and conjectures, you never get educated.”
(Mark Twain, 1906)

“With 14 million new cases and 8 million related deaths in 2012 cancer is a major
cause of morbidity and mortality worldwide”[1]. The technology of radiotherapy
planning and delivery is constantly evolving to meet the challenge of safely
delivering a therapeutic dose to cancerous tissues. A prerequisite to delivering
safe, precise radiotherapy is understanding the sources and impact of
uncertainty in each step of the treatment chain[2]. When determining the benefit
or otherwise of new technologies and techniques through clinical trials,
rigorous methodology must be adopted to ensure protocol compliance[3].

The accuracy and precision of radiation therapy has improved in recent times
through advances in radiation delivery systems and image guidance. Although,
some aspects, with respect to the accuracy and precision with which treatments
are prescribed and planned have improved, it has not been to the same extent.
Radiotherapy has moved from 2D to 3D treatment planning and now
incorporates multimodality imaging into the contouring process, but there is
still variation in tumour delineation and inverse planning.[4]. Through the
analysis of delineated 3D images, that is, contours, in radiotherapy planning it is
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possible to investigate a number of aspects of the planning and delivery process
(Figure 1). This thesis is by publications, and is an investigation into the impact
of uncertainty in contouring, planning, and organ motion, on dosimetry and
modelled outcome.

Figure1.1 Radiotherapy process diagram identifying which aspect of the
treatment chain each chapter addresses
The analogy of William Tell shooting the apple from his son’s head (Figure 1.2)
is not new in radiation therapy[5]. But, it is of particular relevance to the work
presented in this thesis; accurately defining and hitting the target while
avoiding injury.
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Figure 1.2 William Tell shooting at the apple, woodcut from Ein Schönes
Spiel…von Wilhelm Thellen, by O. Schweitzer, 1698.

1.1 Account of scientific progress linking the publications
in the thesis
The investigation into contouring variation in radiotherapy began with a review
of the literature. Contouring variation has for a number of years been
recognised as a major uncertainty in radiotherapy[6]. A clinically focused review
had been published earlier[7] but there was no work summarising the methods
of analysis of contouring variation. With the advent of 3D planning in external
beam radiotherapy and brachytherapy, there had been a large increase in the
number of contouring studies being published. Here, a contouring study is
broadly classified as an investigation that analyses the variation between a
number of delineations on medical images in order to elucidate some
information about the planning and delivery process. Most commonly, the

______________________________________________________________________________________________________________________
20

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

information sought is about inter- or intra-observer contouring variation but
may also include the impact of organ motion, image quality, contouring
guidelines, clinical trial protocol evaluation, atlas development and training. The
literature review, presented in chapter 3 identified a number of different
methods of analysis. These techniques were explained with advantages and
disadvantages in particular situations. What was obvious from the literature
was that there was no consensus on the appropriate techniques to use, and that
methods employed were dictated by bespoke software and expertise available
to investigators rather than evidence.

The work presented in chapter 4 aimed to address the issue identified in the
literature review, i.e. the lack of consensus in analysis technique in contouring
studies. This was achieved by establishing which contouring variation metrics
were most likely to impact on dosimetry and modelled outcome and therefore,
be most relevant to reporting. The impact of contouring variation on dosimetry
had been investigated previously[8-10], but this was the first study assessing the
correlation between these two factors. The contouring variation metrics that
were most significantly correlated with modelled outcome were identified for
conformal lung cancer radiotherapy. This work presented a methodology that
could be employed in other tumour sites and treatment techniques to ascertain
the most relevant metrics of contouring variation to report. This work was
repeated for head and neck cancer inversely planned radiotherapy, see
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Appendix A. The best achievable contouring concordance between planning
systems was investigated by our group using a phantom study, see Appendix B.

Similar to contouring uncertainty, inter-observer variation in radiotherapy
planning has been identified as a confounding factor on radiotherapy trials [11].
The International Commission on Radiological Units (ICRU) has outlined
procedures for prescribing and reporting in radiotherapy[12-14] that guide the
planning process. In the context of inverse planning there may be inter-observer
variation due to planner experience with respect to adjusting parameters to
achieve the end result. A study assessing the impact of planner experience on
dosimetry is presented in chapter 5. This work demonstrated that planner
experience can influence both plan quality and delivery efficiency in the context
of head and neck inverse planning.

The resulting dosimetric impact of day-to-day organ deformation and position
can be similar to that of contouring variation. Involving both systematic and
random uncertainties, see section 2.2.2.1. Therefore, similar analysis techniques
to those used in chapter 4 can be employed to assess the dosimetric impact of
organ motion using contoured daily cone beam computed tomography (CBCT)
imaging. Endo-rectal balloons (ERBs) have been used extensively in prostate
radiotherapy[15] to stabilise the prostate and minimise the amount of rectal wall
in the high dose area. The use of ERBs in the post-prostatectomy setting had not
been investigated to the same extent. Chapters 6 and 7 employ similar analysis
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techniques to those used in chapter 4 to assess the impact of organ motion on
dosimetry and margins with and without the ERB. This was the first study
published investigating the day-to-day reproducibility of the prostate bed with
the ERB in situ. The significance of the findings were that ERBs did reduce organ
motion, particularly for the rectum. Further study is warranted to confirm
whether this translates into better dosimetric reproducibility with a larger
patient cohort.

Contouring and dosimetric uncertainty has been shown to be a major
confounding factor in radiotherapy clinical trials[16]. Yet, there are a number of
other uncertainties in clinical trials, that is, predicted treatment response,
combined modality treatment effect, patient dropout etc. The difference in these
uncertainties in the response rate and patient dropout are routinely accounted
for in sample size calculations for clinical trials. Using the analysis techniques
from previous chapters, it is possible to ascertain the uncertainty in modelled
outcome due to contouring and planning uncertainty. The study presented in
chapter 8 details the results of a benchmarking study for the PORTEC3 trial[17].
PORTEC3 is a phase III clinical trial comparing concurrent chemoradiation and
adjuvant chemoradiotherapy with pelvic radiation alone in high risk advanced
stage endometrial carcinoma. The benchmarking study quantified the
contouring and planning variation amongst participating centres adhering to
the same protocol in Australia and New Zealand. Chapter 9 utilised the
contouring and modelled outcome analysis techniques mentioned above to
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establish impact of contouring variation for the PORTEC3 trial. This work
presented a novel technique for incorporating contouring uncertainty into the
sample size calculation for a randomised controlled trial (RCT).

1.2 Specific aims and objectives

1.2.1 The impact of contouring variation on modelled radiotherapy
outcome

For some treatment sites, the uncertainty in radiotherapy target delineation is
greater than that of organ motion and setup error[7].

As radiotherapy treatment techniques have become more conformal, the
relative importance of contouring uncertainty has increased compared to other
sources of error in the treatment chain[7]. While many studies have analysed
contouring uncertainty geometrically, few have considered the potential impact
on dosimetry[18].

Given varying anatomy and treatment goals, certain clinical sites may be more
susceptible to dosimetric impacts of contouring variation than others.
Understanding the impact of contouring variation on modelled outcome would
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aid in the development of contouring guidelines, adaptive radiotherapy
protocols and clinical trial quality assurance.

Research question:

What is the relationship between contouring variation and predicted
outcome using radiobiological modelling for non-small cell lung cancer
(NSCLC)?

Chapter 4 analyses the correlation between geometric contouring variation and
tumour control probability (TCP) for a series of NSCLC patients.

1.2.2 The influence of planner experience on IMRT plan quality

Intensity modulated radiation therapy (IMRT) has become the standard of care
for a number of treatment sites and is performed in over 90% of Australian
centres[19]. The advantage of IMRT over standard conformal techniques is the
ability to sculpt the dose distribution around sensitive healthy tissues[20]. This
increased conformity comes at the expense of increased plan complexity and
delivery time[21]. In the context of clinical trials, variation in treatment planning
approaches, and the experience of centres in IMRT planning, has been shown to
result in variation in treatment plans[22]. There are a variety of techniques
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available for producing an IMRT plan and planner experience may have an
impact on the final plan quality.

Research question:

What is the impact of planner experience on the quality of radiotherapy
treatment plans in the head and neck region?

Chapter 5 presents an analysis of head and neck IMRT plans generated by six
different planners of varying IMRT planning experience.

1.2.3 Investigation of organ motion, dosimetry, and margins in the
presence of organ stabilising devices

Adjuvant radiotherapy delivered post radical prostatectomy results in longer
time to biochemical failure and improved local control compared to
surveillance[23]. There is also a survival benefit associated with adjuvant
radiotherapy for patients <70 years old or who had positive surgical margins [23].
It should be noted, these results are derived from the pre-prostate speficic
antigen era and are currently under investigation in a number phase three
randomised trials[24, 25]. Owing to excellent target coverage and critical structure
sparing, intensity modulated treatment techniques are the preferred method of
treatment delivery in post prostatectomy radiotherapy.
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The target volume in post prostatectomy radiotherapy is bounded by the
bladder and rectum and therefore may experience deformation due to organ
motion. Furthermore, bladder and rectal changes day to day can be
significant[26].

Endo-rectal balloons have been used to stabilise anatomy extensively in intact
prostate radiotherapy[27]. It remains to be demonstrated if endo-rectal balloons
actually improve dosimetric reproducibility on a day-to-day basis.

Research questions:

Does the use of an endo-rectal balloon in situ improve dosimetric precision
in post-prostatectomy radiotherapy?

Does the use of endo-rectal balloons reduce the required planning target
volume (PTV) margin for organ motion in post prostatectomy patients?

Chapter 6 presents a geometric and dosimetric comparison of two cohorts of
post-prostatectomy patients treated with and without an endo-rectal balloon in
situ. Chapter 7 uses the same cohort of patients studied in chapter 6 but
specifically analyses organ motion and the required PTV margin to account for
it.
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1.2.4 Benchmarking and assessing the impact of contouring
variation in radiotherapy clinical trials

A randomised controlled trial (RCT) is the most effective means available to
answer questions about treatment effectiveness when designed, conducted and
reported appropriately[28]. It is well recognised that robust methodology and
quality assurance (QA) is required to ensure the validity of RCTs[29].

Accurate delineation of target volumes and organs at risk for radiation therapy
planning is required for high quality treatment as it has a direct flow-on effect
for the rest of the radiotherapy chain. The ability of clinicians to contour
according to protocol has been investigated for a number of RCTs[16, 30-33]. The
accuracy and consistency of contouring in a RCT may be affected by
heterogeneity within contributing institutions technology and experience[7].

Protocol deviations in RCTs have been found to result in a significant decrease
in survival and local control[16]. In some cases the magnitude of the detrimental
effect can be larger than the anticipated benefits of the interventions involved[16,
34].

Implementation of appropriate QA of radiotherapy measures for clinical

trials has been found to result in fewer deviations from protocol[35].
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The modelled impact of dosimetric uncertainty on sample size for RCTs showed
that reduced uncertainty in dose resulted in a significant reduction in required
patient numbers[36]. Dosimetric uncertainty is influenced by contouring
variation and has been demonstrated to be significant for a number of clinical
sites[37-39].

Research questions:

What is the magnitude of endometrial cancer contouring variation in
Australia and New Zealand?

What is the impact of contouring variation on the statistical power of
clinical trials and can it be accounted for by ensuring optimum patient trial
recruitment numbers?

Chapter 8 presents the results of a benchmarking QA study performed in
Australia and New Zealand for the PORTEC3 RCT[17]. Chapter 9 assesses the
impact of contouring variation on clinical trial design using the benchmarking
dataset from the PORTEC3 clinical trial.
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1.3 The journey
The research presented in this thesis was undertaken in the School of Physics
within the Faculty of Engineering and information Sciences. Expertise and
laboratory support was provided within the Centre for Medical Radiation
Physics, at the University of Wollongong. Treatment planning facilities and
clinical research supervision were also provided by the Liverpool Cancer
Therapy Centre (LCTC) and the Ingham Institute for Applied Medical Research
where most of the day to day research was undertaken. The Illawarra Cancer
Care Centre (ICCC) at Wollongong Hospital also provided data and clinical
guidance for a portion of the research undertaken. The contouring, planning and
organ motion studies were performed at LCTC. The clinical trial QA and
statistical power studies were completed at ICCC.
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Chapter 2: Literature review
2.1 Radiotherapy
2.1.1 Cancer and the role of radiotherapy
In Australia, excluding non-melanoma skin cancer, 123920 people were
diagnosed with cancer in 2014[40]. Although the mortality rates from cancer are
falling, in 2014 cancer related deaths still accounted for approximately 3/10 of
all deaths in Australia[40]. The five year overall survival of cancer patients has
improved in Australia from 46% in 1982-1986 to 67% in 2007-2011, however
this has not been consistent across all tumour types[40]. In 2014 the most
commonly diagnosed cancers in males were estimated to be prostate, bowel,
skin (melanoma), lung and head and neck[40]. While in women the most
commonly diagnosed cancer sites were estimated to be breast, bowel, skin
(melanoma), lung, and uterine[40].

In 2013 the Collaboration for Cancer Outcomes Research and Evaluation
(CCORE) provided a report to the Australian government department of health
and aging reviewing optimal radiotherapy utilisation rates[41]. These rates
estimate the number as a percentage of diagnosed cancer patients that would be
treated with each resource as part of an optimal treatment regimen. The
reported optimal rates of radiotherapy and brachytherapy were 48.3% and
3.3%, while chemotherapy was 8.9%[41]. Meaning, that in the Australian setting,
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based on the best available data, radiotherapy is indicated for 48.3% of
notifiable cancers, either delivered as a monotherapy or in combination with
chemotherapy or brachytherapy[41].

Figure 2.1 From Thariat et al[42]. Timeline of radiotherapy evolution from the
discovery of X-rays by Röntgen to modern intensity modulated techniques.

2.1.2 Trends in radiotherapy treatment delivery
The discovery of X-rays by German physicist Wilhelm Röntgen in 1895 heralded
the beginning of the use of radiation in medicine (Figure 2.1)[43]. Although it
should be noted that the rays Röntgen named, and was the first to
systematically describe, were also studied in the 1800s by various others[44].
The time between discovery and reported first use of X-rays for a medical
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purpose was 60 days[45], although, there is some debate as to whether this is
historically correct. The first verifiable reported use of X-rays medically was in
Stockholm[46] to treat basal cell carcinoma and was reported at the 1899
Swedish Society of Medicine meeting.

The first 40 years of radiotherapy was dominated by the use of kilovoltage X-ray
beams. These were categorised into soft, medium and hard X-rays by
penetrative properties. The lower energy beams were used to treat a variety of
skin cancers, dermatological and inflammatory conditions in the era before
antibiotics and steroids[44,

47].

While the higher energy or harder beams were

used to treat deep-seated tumours. There are a number of drawbacks to treating
deep tumours with kilovoltage energies; the dose to skin and overlying tissues
is quite high due to attenuation of the low energy beam, absorption in bone and
long treatment times[48].

Teletherapy (external beam) devices using Radium were also manufactured in
North America and Europe[44]. With the advent of nuclear reactors man-made
isotopes became available in 1948, and Cobalt-60 was used as a Teletherapy
source widely for 20-30 years[42]. Linear accelerators (linacs) were developed
before and during the second world war and the first electron accelerator
designed for medical use was installed in the Hammersmith hospital, London in
1953[48]. The first patient treated in North America with a 6 MV linac was at
Stanford in 1956[49]. Both Co-60 and linac based mega-voltage therapies allowed
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skin-sparing application of radiation dose to deep tumours in the pelvis and
thorax for the first time.

The first computed tomography (CT) image of a patient was acquired in 1971 [50]
and in the 1980s was being implemented in radiotherapy departments[42]. This
permitted more accurate definition of the tumour and healthy tissues. Dose
distributions could now be sculpted in three dimensions (3D) using treatment
planning systems (TPS) with beams eye view and linacs with multileaf
collimators (MLCs). This so called 3D-conformal radiotherapy saw many
tumour sites benefit from higher doses and improved organ at risk (OAR)
sparing[42].

Intensity modulated radiation therapy (IMRT) was first proposed by Brahme[51]
in 1988 and started entering clinics due to technology advances (e.g. MLC) in
the late 1990s[52]. IMRT modulates the intensity of the radiation to enable
precise shaping of the dose distribution to the target while avoiding healthy
tissue[21]. There are a variety of different techniques for delivering IMRT
including; beam compensators[53], and MLCs in both step and shoot[54] and
sliding window mode[55]. Volumetric modulated arc therapy (VMAT), first
proposed by Yu[56] (called Intensity Modulated Arc Therapy) in 1995, is a form
of rotational IMRT and has become standard of care in many centres. This was
later refined by Otto[57] to improve the optimisation technique required to
generate a plan.
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2.2 Radiotherapy treatment planning
Radiotherapy treatment planning is the process in which the tumour and
healthy tissues are defined in 3D and used to generate a dose distribution that
will guide the technical delivery of the beam by the treatment machine (Figure
2.2). With the increasing use of computers in radiotherapy, treatment planning
has evolved from 2D radiographs to multiple 3D datasets that include both high
resolution anatomical information and functional information. Computers have
also had an influence on beam delivery, from standard open fields using beamseye-view to intensity modulated beams that closely shape the dose to targets
while avoiding healthy tissues.

Figure 2.2 Radiotherapy process including treatment planning steps in red, from
Gupta et al[58]

2.2.1 Imaging
Radiotherapy planning relies largely on 3D imaging. CT was the first imaging
modality that allowed the visualisation of the tumour in relation to the
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surrounding tissues in 3D. CT also provides electron density information, which
is required for understanding radiation transport in tissue. However, soft tissue
definition on CT images can be poor and lead to target delineation
uncertainties[59]. Other imaging modalities can be registered with CT to better
delineate the location of tumours and OARs. Magnetic resonance imaging can
provide excellent anatomical soft tissue definition[59]. Other functional imaging
techniques include positron emission tomography (PET) and single photon
emission tomography (SPECT).

2.2.1.1 Positron Emission Tomography (PET)
PET imaging has been shown to improve target delineation in a number of
treatment sites, particularly head and neck, and lungs[60]. Different molecular
imaging agents enable the visualisation of different tumour characteristics
including metabolism (FDG), hypoxia (FMISO), and proliferation (FLT). PET
imaging can also be used for response assessment and may prove valuable in
the setting of adaptive radiotherapy[61].

2.2.1.2 Magnetic Resonance Imaging (MRI)
MRI refers to the production of 2D and 3D images that correspond to the
macroscopic density distribution of nuclear spins within the volume being
imaged[62, 63]. MRI can provide excellent soft tissue definition in areas that CT
does not, for example, defining the apex of the prostate. In recent times, there
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has been accelerated research growth in the application of MRI to
radiotherapy[64]. This is in part due to a lack of ionising radiation required for
imaging as well as newer MRI scanners having wide bore designs that can
accommodate patient immobilisation devices[65]. MRI can also be used to image
functional characteristics of tumours and healthy tissues. Diffusion weighted
imaging (DWI) makes use of the limited diffusion of water molecules to
generate an image and therefore is a measure of cellularity. DWI may prove
useful for treatment response assessment in a number of tumour sites[66]. Two
factors limiting the uptake of MRI in radiotherapy is the lack of required
electron density information for dose calculation[67] and geometric distortion[68].

2.2.2 Contouring
Contouring refers to the process of segmenting anatomical structures on digital
images[69]. This is of particular importance in radiotherapy planning as the
segmentation of tumour and healthy tissues is used to guide the treatment and
identify areas to be avoided. Technically contouring can be performed on any
image type but CT is typically used as it is required for dose calculation by the
major treatment planning system vendors[69]. It is commonplace in radiotherapy
planning for PET and MRI data to be registered to the planning CT to aid in
defining primary tumours and involved nodal regions.
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It is widely accepted that contouring is one of the largest sources of uncertainty
in the radiotherapy treatment process[70]. Assessing this uncertainty is difficult
due to the lack of a derivable ground truth from imaging data[69]. It is, in theory,
possible to establish ground truth through invasive techniques (surgical
intervention or biopsy) but in practice this is impractical and has additional
uncertainty when registering specimens to imaging data[71]. Alternatively
investigators assess variation from different physicians (inter-observer) or the
same physician (intra-observer) and in a number of different clinical situations
(see contouring studies section).

In radiotherapy planning for the individual patient, the dosimetric accuracy is
closely related to quality of contouring.[69]. Manual delineation is currently the
most widely used method of target and normal structure contouring, which is
time consuming and subject to error for the reasons mentioned above. Reducing
contouring time and achieving universally precise contours is the goal of
automated contouring[69]. Indeed, automated contouring is required in adaptive
radiotherapy where many datasets need to be delineated quickly, accurately
and consistently[69]. Highly accurate automatic segmentations are currently
achievable for some organs and image types but there are still a number of
challenges to be faced including image artefact, patient specific features, organ
motion and unpredictable shapes of abnormal tumour growth[69].
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2.2.2.1 Volumes and margins
To ensure consistent definition of dose distributions in three-dimensional space
the ICRU has proposed a set of principles. These principles, for prescribing,
recording and reporting photon beam therapy have been published in a number
of reports[12, 13, 72]. These reports describe a number of volumes to be used in
defining radiotherapy treatments (Figure 1.3). The gross tumour volume (GTV)
is the macroscopic extent of malignant growth as determined by palpation or
imaging. The clinical target volume (CTV) is the volume which contains the GTV
and any microscopic malignant disease. The planning target volume (PTV) is a
volume which contains the CTV plus a margin to account for organ, tumour, and
patient movement, and uncertainty in delineation and setup. The treated
volume and irradiated volumes are defined as the volume of the prescription
and tissue volume which receives a dose that is considered significant in
relation to normal tissue tolerance. The internal target volume (ITV) is the
volume that accounts for movement and deformation of the CTV due to
physiological processes. The organs at risk (OARs) or critical normal structures
are tissues that might influence treatment planning or prescription through
potential morbidity if irradiated. The planning organ at risk volume (PRV) is the
OAR plus a margin to account for uncertainties and variations in position and
definition to avoid serious complication. The remaining volume at risk (RVR) is
the imaged volume, excluding any contoured OARs and CTVs.
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Figure 1.3 Diagram showing the relationship between different treatment
volumes as defined by ICRU report 62[13]
In defining the PTV margin one must account for geometric uncertainties in the
treatment planning and treatment process. These include tumour delineation
(see Section 2.3), unknown extent of microscopic spread of malignant disease,
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organ motion and patient setup[73,

74].

To calculate the required margin to

account for these uncertainties, they are commonly classified as systematic or
random[75]. If the mean irradiation geometry of the fractionated treatment
differs from the geometry in the treatment plan this is considered a systematic
error[75]. Variations in position around the mean from fraction to fraction are
considered random errors[75]. Stroom and Heijmen[75] also note that the source
of random and systematic errors may be the same. The impact of systematic
errors is larger than that of random errors and thus in modern margin recipes
these are given a larger weighting[73]. By far the most popular margin recipe is
that of van Herk, Equation 1.
(1)

Where Σ is the standard deviation of the systematic errors and σ is the standard
deviation of the random errors.

2.2.3 Assessing plan quality
Geometric and dosimetric accuracy are closely related in radiotherapy,
contouring dictates where the dose is to be delivered but the quantum of dose
deposited is also important. It has been stated many times in the literature that
deviations of 7-10% in delivered dose can be detected clinically[70, 76, 77]. In his
1984 paper on dosimetric precision Brahme states, “If the normalized dose
response gradient is higher than 3, as is frequently the case, the relative standard
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deviation of mean dose in the target volume should be less than 3 per cent to
achieve an absolute standard deviation in tumour control probability of less than
10 per cent”[78]. Assessing plan quality consists of checking 1) that the plan
matches the treatment intent (i.e. prescription) and 2) that the delivered dose
matches the plan[21]. When evaluating whether a plan matches treatment intent
,the radiation oncologist and the planner can make use of the dose display, dose
volume histograms (DVH) and some planning systems provide tools that allow
for assessment of tumour control probability (TCP) and normal tissue control
probability (NTCP)

[79]

(see Section 2.4). Dose conformity indices were

introduced by the Radiotherapy Oncology Group (RTOG) as method of assessing
how closely and uniformly the prescription isodose conformed to the target
volume[80], Equations 2-4.
(2)

(3)

(4)

Where, Imin is the minimal isodose surrounding the target, RI is the reference
isodose, Imax is the maximum isodose in the target, VRI is the volume of the
reference

isodose and

TV

is

the

target

volume.

Since

the

RTOG

recommendations there have been a variety of different techniques proposed to
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assess the conformity of the prescription dose to the dose to normal tissues in a
general way that enables comparison between studies[80-82].

2.3 Methods of analysis in contouring studies for Radiation
Oncology
Chapter 3 of this thesis is a review article that was published in 2010 and was
the first publication towards this PhD thesis. Chapter 3 provides a detailed
overview of contouring studies and methods of analysis in radiation oncology.
There have been four other reviews in this area[6, 7, 18, 83], all differ slightly in
scope but nonetheless overlap the subject area covered in Chapter 2. Here, a
brief summary of these reviews will be provided outlining common issues
identified in the literature.

Weiss and Hess[7] published a review of the available literature in 2002. The aim
was to evaluate impact of inter-observer variability in contouring on the global
geometric accuracy in radiotherapy. From the literature 18 studies were
identified and reviewed with respect to tumour site, number of patients and
observers, volume of interest and key results. From these studies Weiss and
Hess hypothesised the causes of contouring variation and gave a number of
recommendations including the use of clear protocols, advanced imaging and
peer review to reduce uncertainty.
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Njeh’s[6] commentary in 2008 aimed to bring attention to the issue of
contouring variation as the “weakest link” in the overall radiotherapy treatment
chain. In the article Njeh outlines the planning and delivery process and
definitions of accuracy and precision. Some of the solutions for contouring
variability identified by Njeh include the use of appropriate imaging for
delineation, PETCT in head and neck cancer for example. Njeh also recommends
continued education and peer review as possible solutions to contouring
variation.

The articles by Hanna et al[83] and Fotina et al[18] both deal specifically with the
metrics used to quantify contouring variation. Hanna et al performed a
systematic review using PubMed using search terms relevant to contouring
studies. Hanna et al identified 63 studies across a range of tumour sites, the
most common of which was lung. Fotina et al, is not strictly a review but did
perform a comprehensive literature search of overlap metrics for contour
comparison. They then calculated this metrics for a series of 7 prostate and 8
lung cases that were contoured by 8 observers.

All of the articles save for the review by Njeh acknowledged the issue that there
is no consistent method or form of reporting used for contouring variation
studies, with respect to the number of patients and observers to the metrics of
comparison used. Hanna et al recommended the use of an overlap metric, DICE
similarity index for instance, in combination with volume and centre of mass.
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Fotina et al agreed with Hanna et al but also recommended descriptive statistics
and a statistical measure of agreement.

2.4 Motion in radiotherapy
Motion is a confounding factor in the delivery of effective radiotherapy. Motion
in this context, refers to deviation of the target and normal structures from their
planned position, with respect to the treatment coordinate system. This motion
can occur over a range of time scales. There are a number of methods that have
been proposed to account for motion, these depend on the type and magnitude
of the motion and the treatment site in question (i.e. gating for lung,
transponders for prostate).

2.4.1 Types of motion
The main sources of motion encountered in radiotherapy can be broadly
classified as intra-fraction and inter-fraction motion. Intra-fraction motion is
that which occurs during a treatment fraction. Inter-fraction motion is defined
as motion that occurs between treatment fractions. Motion that operates on
intra-fraction time scales includes: cardiac, respiration, organ filling, peristalsis,
and patient movement. Furthermore, inter-fraction motion can arise from dayto-day differences in organ filling, treatment setup, and response of normal and
tumour volume changes due to radiation[84]. For intra-fraction motion the
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trajectory of the tumour or organ will vary depending on the location within the
body and the fixation of the tumour with respect to its surroundings[85].

2.4.2 Image Guided Radiation Therapy (IGRT)
IGRT refers to the integration of imaging equipment within the treatment room
to acquire images of the patient in the treatment position prior to or during
radiotherapy[86,

87].

Accounting for, and minimising the impact of motion on

radiotherapy treatment is the aim of IGRT. The technologies used to deliver
IGRT are varied in sophistication and complexity, but all use imaging to align the
patient to the planned position. The ideal properties of an IGRT system have
been described by Mageras[88] and include: accuracy and precision, efficiency,
integration, broad application, reduced radiation dose, real time data collection
and cost effectiveness. Radiation based systems may use the mega-voltage
treatment beam to generate an image using an electronic portal imaging device
(EPID) or film. Further, a cone-beam CT (CBCT) may be used, kVCBCT consists
of a kilo-voltage imaging source (usually orthogonal to the treatment beam) and
a flat panel detector. The Tomotherapy system uses the treatment beam with a
reduced energy to generate a mega-voltage fan-beam CT image. Other systems
use multiple kilo-voltage sources stereoscopically to localise bony anatomy or
markers. Non-radiation based IGRT systems may use optical cameras,
electromagnetic tracking, ultrasound or MRI to discern patient anatomy or
markers in order to align the patient with the treatment beam. All of these
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technologies, implementations, commissioning procedures and limitations have
been reviewed in detail by De Los Santos et al[89].

2.4.3 Impact of organ motion on plan quality
When treating a moving target, the delivered dose distribution may not match
that of the treatment plan, which does not typically include uncertainty due to
motion. The extent to which the delivered dose differs from that of the planned
dose depends on how the motion interferes with the delivery, and is of
particular importance in dynamic and modulated deliveries[85]. Motion may
interfere constructively or destructively with MLC motion, gantry rotation,
collimator rotation, or dose rate[85]. The frequency of the motion in question will
also play a role. Inter-fraction motion will cause day-to-day differences from the
planned dose which will average out over the course of treatment. Intra-fraction
motion may cause differences from the planned dose, which is averaged out
over that treatment session. It has been stated previously that these effects will
not constitute a problem as, over many fractions the cumulative impact is to
only slightly smear the dose distribution[90]. But, with the increasing use of
hypofractionated treatment delivery the potential impact of organ motion on
the delivered dose is demanding increased investigation[91].
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2.4.4 Strategies to reduce motion
Depending on the treatment site a number of different motion reduction
techniques have been reported. Thermoplastic masks are now commonplace
fixation devices for the treatment of head and neck patients. These masks are
placed in a water bath to soften and are then moulded to the patient, used daily
for position they can reduce inter-fraction setup error[92]. Abdominal
compression has demonstrated motion reduction for lung and liver treatments
by reducing the amount by which the diaphragm can move freely[93]. A number
of different products have been proposed for prostate radiotherapy. The
Rectafix, is a plastic rod which is inserted into the rectum during simulation and
treatment. The Rectafix increases the separation of the rectum and the prostate
and reduces rectal motion. Endorectal balloons serve a similar purpose in that
they are also inserted into the rectum during simulation and treatment to
stabilise the rectum and move the posterior rectal wall away from the high dose
region[15]. Hydrogel spacers, are injected under transrectal ultrasound guidance
between the rectum and prostate and last for a number of months. The gel
creates a space between the rectum and prostate and results in a reduction in
rectal doses for the majority of the prostate patients[94].

2.4.5 Strategies to account for motion
Pre-treatment imaging can be used to reduce the impact of inter-fraction
motion on the delivered dose. Margins can also be used to account for inter- and
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intra- fraction motion however the aim of IGRT is to reduce treatment margins
and thus the volume of normal tissue irradiated[85]. One of the simplest and
earliest proposed methods of accounting for intra-fraction motion was to only
turn the beam on when the target is inside the beam aperture, this is known as
gating and was proposed in 1980s by a number of investigators[95-97]. For lung
radiotherapy, this requires capturing tumour motion in the planning CT scan
using 4D techniques[98]. Furthermore a respiratory signal needs to be collected
during treatment in order to gate the beam, this signal may come from a bellows
belt, fiducial markers, spriometry, or external surrogate[98]. Breath hold
techniques have also proved useful in gated treatments, whereby the patient
holds their breath at a desired point in the breathing cycle[98]. Currently the
most advanced technique to account for motion of the target during treatment is
realtime tracking[98]. The Cyberknife system uses fiducial markers and
fluoroscopic techniques to track target motion and compensate with a robotic
treatment unit[99]. Recently Keall et al[100] reported on the use of
electromagnetic fiducials to guide dynamic MLC tracking of prostate
radiotherapy.

2.5 Radiobiological modelling
Radiobiology underpins the discipline of radiation oncology. Classical
radiobiology informed modern developments in fractionation, the linear
quadratic model, and our understanding of the repair of radiation damage[101].
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However, radiobiology also holds promise in elucidating methods of
optimisation of biological and physical factors for personalised biologically
based treatment planning[101]. Radiobiological modelling is a valuable tool in the
assessment of complex radiotherapy treatment plans[102]. For example, the
comparison of IMRT and conformal plans for prostate radiotherapy[103] or stepand-shoot IMRT verse Tomotherapy for head and neck cancer[104].

2.5.1 Mechanisms of radiation induced cell death
Radiotherapy exploits the ability of radiation to induce death in cells, of
particularly interest is the death of tumour cells. There are a number of ways in
which radiation can cause the death of a cell and, these are influenced by the
DNA damage response (DDR) system[105], here death is classified as the inability
of a cell to proliferate. How and when cells die is determined by the DDR, which
can vary between different types of tumour and normal cells and within
populations of tumour cells[105]. The characteristics of different types of cell
death are outlined in Table 2.1. Apoptosis is a highly regulated form of cell death
that is an essential and normal part of many physiological processes, which can
be induced by irradiation[105]. Autophagy translated means ‘self-eating’ and
refers to a process where cells consume their own cytoplasm. Autophagy has
been observed post irradiation although it is not clear if it is the cell trying to
survive or dying in this context[105]. Mitotic catastrophe is the process whereby a
cell dies while it is dividing, usually due to entering into mitosis with some
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accumulated DNA damage[105]. Necrosis occurs when conditions are
incompatible with normal cellular processes, i.e. exposure to radiation[105].
When cells permanently lose the ability to divide they are classified as
senescent[105], radiation induced DNA damage can cause senescence in cells[106].
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Type of cell death
Apoptosis

Autophagy

Table 2.1 Characteristics of different types of cell death from Okada and Mak [107]
Morphological changes
Biochemical
Common detection methods
features
Nucleus
Cell
Cytoplasm
membrane
Chromatin
Blebbing
Fragmentation
Caspase
Electron microscopy; TUNEL
condensation;
(formation
of dependent
staining; annexin staining;
nuclear
apoptotic bodies)
caspase-activity assays; DNAfragmentation;
fragmentation assays; detection
DNA laddering
of increased number of cells in
subG1/G0; detection of changes
in mitochondrial membrane
potential
Partial chromatic Blebbing
condensation; no
DNA laddering

Increased number of Caspaseautophagic vesicles
independent;
increase
lysosomal
activity

Electron microscopy; proteindegradation assays; assays for
marker protein translocation to
autophagic membranes; MDC
staining
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Mitotic catastrophe

Multiple
micronuclei;
Nuclear
fragmentaion

Necrosis

Clumping
random
degradation
nuclear DNA

Senescence

Distinct
hetrochromatic
structure
(senescence
associated
hetrochromatic
foci)

-

and Swelling;
rupture
of

-

-

CaspaseElectron microscopy; assays for
independent (at mitotic
markers
(MPM2);
early
stage) TUNEL staining
abnormal
CDK1/cyclin B
activation

Increased
vacuolation;
mitochondrial
swelling

-

Electron microscopy; nuclear
staining (usually negative);
detection of inflammation and
damage in surrounding tissues

Flattening
increased
granularity

and SA-β-gal activity Electron microscopy; SA-β-gal
staining; growth-arrest assays;
assays for increased p53, INK4A
and ARF
levels
(usually
increased); assays for RB
phosphorylation
(usually
hypophosphorykated); assays
for metalloproteinase activity
(usually upregulated)
CDK1, cycline-dependent kinase 1; MDC, monodansylcadaverine; MPM2, mitotic phosphoprotein 2; SA-β-gal, senescence-associated βgalactosidase;
RB
retinoblastoma
protein.
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2.5.2 The Rs of radiobiology
Fractionation in radiotherapy was a consequence of technological limitations of
early X-ray equipment[108] but was later developed through experiments
performed in France in the 1920s[109], the goal of these experiments was to
sterilise rams using kV radiation. It was observed that skin damage could be
reduced if the total dose was divided into multiple small fractions. It was after
this that fractionation began to be used in radiotherapy, exploiting repair and
repopulation to spare normal tissues and reoxygenation and redistribution to
damage the tumour[86]. The Rs of radiobiology (Figure 1.4) are; repair,
repopulation, redistribution, reoxygenation and radiosensitivity. Repair refers
to the process by which the function of a cell is restored after acquiring some
damage from irradiation. Radiation can cause single and double strand breaks
to DNA, 1 Gy will cause about 1000 single strand breaks and 40 DSB [110].
Depending on the type of strand break the cell may employ excision repair,
mismatch repair or recombination repair[86]. Repopulation refers to the process
whereby surviving cells, after irradiation, begin to proliferate. Redistribution or
reassortment of cells within the cell cycle is a regular occurrence in
homeostasis. It is important in radiotherapy however as different phases of the
cell cycle are more sensitive to radiation than others with M phase most
sensitive and S most resistant[86]. Reoxygenation of cells is important in
radiotherapy as oxygenated cells are more sensitive to radiation damage and
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hypoxic cells are more resistant[86]. There are a multiplicity of factors that
influence radiosensitivity of human tumours which are broadly classified into
tumour (hypoxia, tumour kinetics and number of clonegens), host (defence,
volume effect and genetic predisposition) and treatment (dose, type of radiation
and fractionation) factors[86].

Radiosenstivity

Repopulation

Redistribution

Radiobiology

Repair

Reoxygenation

Figure 1.4 The R’s of radiobiology

2.5.3 The linear quadratic model
The linear quadratic (LQ) model uses a second order polynomial with a zero
constant term to fit cell survival data[111]. The formula for cell survival is then:
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( )
(5)
(

)

Where D is the dose and α and β are constants. The LQ model is favoured over
other power law models because it gives a more accurate description of cell
survival for low doses[111]. The shape of the curve (Figure 2.3) for this model is
determined by the ratio of α Gy-1 and β Gy-2, α/β Gy can be seen in figure 10 as
the point on the curve at which the damage from the linear and quadratic
components is equal[111]. This model has been in wide spread use for a number
of years owing to its ability to accurately predict radiation response both in vitro
and in vivo[111].

Figure 2.3 The linear Quadratic model
from Joiner, 2009
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2.5.4 Equivalent Uniform Dose (EUD)
EUD was proposed by Niemierko in 1997 and is defined as the uniform dose
that, if delivered over the same number of fractions as the non-uniform dose
distribution of interest, yields the same radiobiological effect[112]. In 1999
Niemierko extended the notion of EUD to normal tissues with the generalised
EUD[113]:

(∑

(6)

)

Where vi is the fractional organ volume receiving the dose Di and a is a
parameter describing the volume effect which is tissue specific.

2.5.5 Tumour Control Probability (TCP)
Radiation dose response curves are sigmoidal in shape with the likelihood of a
radiation effect increasing with increasing dose. There are three standard
approaches that have been commonly used to mathematically model doseresponse; Poisson, logistic and probit[114,

115].

The only model with a

radiobiological background is the Poisson model as it is based on the Poisson
statistical model of cell kill[116]:

( )

*

(

⁄

)+

(7)
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Where D50 is the 50% response dose and γ is the maximum value of the
normalised dose response gradient. The logistic model is widely used in biology
applications,

outside

of

radiation

oncology,

for

estimating

response

probabilities[115]. One of the drawbacks of this model is that there is no simple
mechanistic basis and, therefore, no biological interpretation of its
parameters[115]. Despite this, the logistic model enjoys widespread use in
radiobiology to describe dose response in empirical TCP models. For example,
Källman et al [116] used:
( )
*

(8)

+

The probit model has been used for its ease of computation when
approximating the Poisson model[116,

117].

It is also useful for estimating the

impact of dosimetric and biological uncertainties[116, 117]:
( )

[

[√

(

)]]

(9)

2.5.6 Normal tissue complication probability (NTCP)
One of the most widely used NTCP models, particularly in north America, is the
Lyman model[118]. This model calculates NTCP as function of uniformly
irradiated dose in a fractional organ volume[119]:
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(

)

⁄

(

∫

⁄ )

Where;
( ))
⁄(

(

( )

(10)
( ))

( )

Where D is the dose to the irradiated volume fraction v, the m parameter
determines the slope of the NTCP curve at 50% complications, TD50(v) is the
dose that gives an NTCP of 50%. The Lyman model assumes a power law
relationship between tolerance dose and irradiated volume fraction although
there is no biological basis for this. Instead, it is a mathematically convenient
technique that agrees with clinical data, here n is restricted to values 0-1[120]. In
order to use this model with non-uniform dose distributions, histogram
reduction techniques are used, the most common of which is the KutcherBurman[121] method.

The volume and structure of tissue irradiated is an important factor when
considering clinical tolerance[122]. The concept of functional subunits (FSUs) was
introduced by Withers et al[123] in 1988. FSUs are defined (with respect to
tumour) as the largest tissue volume, or unit of cells, that can be regenerated
from a single surviving clonogenic cell. Within an organ FSUs can be arranged in
a parallel or serial architecture. In a parallel architecture it is thought that FSUs
function independently[122], therefore, a threshold volume (i.e. the number of
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irradiated FSUs) must be considered. The risk of complication in a parallel
organ depends on the total dose and is less influenced by hot spots. Parallel
organs include the kidney, liver and lung[122]. In serial organs the function of
that organ is dependent on each individual FSU. Serial organs include the spinal
cord, intestine and oesophagus[122]. As the function of the organ depends on the
function of each FSU, hotspots are important in predicting clinical response[122].

Kallman et al[116] introduced the relative seriality or s-model in 1992 which was
designed to describe the response of an organ with a mixture of serial and
parallel FSUs:

⁄

{

( ) ] }

∏[

(11)

Where, vi is the organ volume receiving a dose Di and P(Di) is the complication.
The parameter s describe the relative contributions of the serial and parallel
tissue architectures with a value of one for completely serial and zero for
completely parallel[114].

Emami et al[124] in 1991 published a paper that outlined normal tissue radiation
tolerance doses according to how much of the organ is irradiated, 1/3, 2/3 or
the whole volume. Due the paucity of available data for all relevant organs the
expert panel took the approach of using consensus to determine the tolerance

______________________________________________________________________________________________________________________
60

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

doses. In the same issue of the journal Burman et al fit the Lyman model to the
data presented by Emami et al to provide estimated NTCP. The Quantitative
Analysis of Normal Tissue Effects in the Clinic (QUANTEC) report was published
in the international journal or radiation oncology biology physics in 2010[125].
This was a series of reviews and vision papers that aimed to provide focused
summaries of dose/volume/outcome data for a number of organs relevant to
radiotherapy as the first significant update since the Emami data[125]. Some of
the values reported in the special edition include lung whole organ V20≤30% to
ensure no greater that 20% chance of symptomatic pneumonitis or rectal whole
organ V75<15% for <15% chance of ≥ grade 2 late rectal toxicity[126]. Some
limitations, areas for improvement and opportunities for future research were
also identified[127-131].

2.6 Radiotherapy clinical trials
The first randomised, medical therapeutic clinical trial was run by Hill in 194648 and demonstrated that streptomycin was superior to bed rest alone for the
treatment of tuberculosis[132], Sir Austin Bradford Hill said of the trial that it
“can be seen to have ushered in a new era of medicine”. The earliest trials in
radiation oncology were conducted in Manchester, England, in 1948[133], and
involved the investigation of breast cancer. There were a number of trials
conducted in North America in the 1950s examining the role of radiotherapy in
breast and lung cancer[133]. Two trials in the 1960s made an impact on patient
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management, an early Hodgkin disease and locally advanced prostate cancer
trial where radiotherapy was investigated as a primary curative treatment[133].
After a number of years of smaller national and cooperative groups in Europe
and North America performing trials there was a need for a more unified
multidisciplinary approach. This new approach saw the formation of the
radiation oncology group (ROG)[134] within the European organisation for
research and treatment of cancer (EORTC) and radiation therapy oncology
group (RTOG)[133] within the National Cancer Institute (NCI). In Australia and
New Zealand the Trans-Tasman radiation oncology group (TROG) was formed
in 1989. All of these organisations recognise the important role of QA in
ensuring the quality of radiotherapy trial data in terms of integrity, consistency,
reliability and accuracy[134].

2.6.1 Trial design and sample size calculations
The results of clinical trials underpin the modern healthcare system, it is
therefore desirable that they are designed and run punctiliously. The elements
of good trial design include[132, 135, 136]:
I.
II.

clearly stated objectives, specification of eligibility
treatments and endpoints

III.

determination of detectable treatment difference

IV.

specification of treatment assignment

V.
VI.

sample size assumptions
reporting
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There are a number of different types of clinical trial, which may be broadly
classified into ‘phases’ based on the general intent of the trial. Phase I trials are
designed to determine the maximum tolerated dose of a new agent[132]. Phase II
trials are used to test new treatments that show promise for an anti-cancer
effect[132]. The goal of phase III or randomised controlled trials is to compare
treatment regimens. From the CONSORT 2010 statement[135] “Randomised
controlled trials, when appropriately designed, conducted, and reported, represent
the gold standard in evaluating healthcare interventions”, the statement goes on
to say “however, randomised trials can yield biased results if they lack
methodological rigour”.

One of the key areas in which RCTs can lack rigour is sample size calculation[137].
The four basic components of a sample size calculation for a comparative study
are; Type I error (α), power, event rate in the control group, and a treatment
effect[138]. A Type I error (α) is defined as a false positive (treatment A is found
to be superior to treatment B when, in fact, it is not) and a Type II error (β) is a
false negative (treatment A is found to be no better than treatment B when, in
fact, it is). Conventionally α is set at 0.05 which equates to a 5% chance of
making a false positive conclusion, and β is set to 0.20 or a 20% chance of a false
negative conclusion[138]. The power is the probability of rejecting the false
negative conclusion and is thus the 1- β, which would equal 0.80 or 80% for the
previous example.
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2.6.2 Quality assurance in radiotherapy clinical trials
Quality assurance in radiotherapy clinical trials has increased in recent times
through cooperative trial research groups like TROG, RTOG, and EORTC. There
are also efforts underway to harmonise quality assurance processes
internationally to create a more homogeneous approach[35,

139].

It was

demonstrated by Peters et al[140] that poor quality non-compliant head and neck
radiotherapy was associated with a 20% reduction in overall survival. A
conclusion that was only possible due to the availability of trial QA data for
retrospective analysis. Furthermore it has been shown through secondary
analysis that protocol deviations may predict poor outcomes[141].

2.6.2.1 Types of quality assurance strategies
Quality assurance requirements for sites wishing to participate in EORTC
clinical trials have been classified into five different levels[142]. Level 1 consists
of a facility questionnaire and an external reference dosimetry audit. Level 2 is a
benchmarking or dummy run exercise. Level 3 involves performing case
reviews or audits on a limited number of cases. Level 4 requires extensive case
review or audit. Level 5 involves performing a complex dosimetry audit.

The facility questionnaire usually consists of a structured document that is filled
in by a participating institution with information pertaining to; available
technology, treatment techniques, staffing, and treatment workload[142].
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Dosimetry audits have been carried out by various organisations for many
years[143-145] as there are many local department factors that can influence
calibration, including; staff skill level, available equipment, adherence to
protocols and secondary standards laboratory used[142]. Benchmarking or
dummy run exercises involve providing trial investigators with data from a
typical case and asking them to ‘treat’ the case using the trial protocol[146, 147].
Benchmarking exercises can be performed at any time during trial recruitment
but are ideally run before site activation. If there are large deviations from trial
protocol the site can be notified and the benchmarking repeated. Benchmarking
exercises can also be useful in drawing attention to shortcoming and
ambiguities in the protocol[142]. Case review or audit involves planning data
being sent to a centralised facility for review of compliance with trial protocol.
There are a number of treatment planning items that can be verified using case
audits including contouring of targets and OARs, dosimetry, imaging, and
planning techniques[142]. Complex dosimetry checks are performed to ensure
that departments can actually plan and deliver complicated radiotherapy
treatments. These typically involve generating a plan on a physical phantom and
then delivering that plan to the phantom and measuring the dose[148].

2.6.2.2 Impact of quality on clinical trial outcome
It has been reported that the quality of the radiotherapy delivered in a clinical
trial can impact on the outcome of that trial

[140, 146, 149].

Further, a decrease in

variation in absorbed dose in a clinical trial can lead to a significant reduction in
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the sample size required to answer the trial question[36]. In a meta-analysis of
eight cooperative group trials Ohri et al[141] reported that protocol deviations
were associated with increased risk of treatment failure and increased
mortality. In a review of EORTC dummy run literature Fairchild et al

[146]

reported that if a centre had taken part in a credentialing exercise they were
more likely have positive results in future individual case audits.
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a b s t r a c t
Background and purpose: Contouring variation is a well know uncertainty in modern radiotherapy. This
study investigates the relationship between contouring variation, tumor control probability (TCP) and
equivalent uniform dose (EUD) for conformal non-small cell lung cancer (NSCLC) radiotherapy.
Material and methods: Seven patients were retrospectively recruited to the study and multiple PTV contours were generated based on CT and PET imaging by three observers. Plans were created for each PTV
volume. Volumes were analyzed geometrically using volume, location, dimension and conformity index
(CI). Radiobiological plan analysis consisted of two TCP models and EUD. Spearman’s correlation coefﬁcient (q) was used to quantify the association between geometric variation and radiobiological metrics.
Results: The variation in CI and TCP for the study was 0.66–0.90% and 0.19–0.68%. Changes in lateral
dimension and volume were signiﬁcantly correlated with TCP and EUD with an average q of 0.49
and 0.43 (p < 0.01) respectively.
Conclusions: TCP and geometric contour variation show signiﬁcant correlation. This correlation was most
signiﬁcant for changes in lateral dimensions of PTV volumes. This association may be used in the
assessment of contouring protocol violations in multicenter clinical trials and aid in the design of future
contouring studies.
Crown Copyright Ó 2014 Published by Elsevier Ireland Ltd. All rights reserved. Radiotherapy and
Oncology 112 (2014) 332–336

Variability in contouring remains one of the largest uncertainties in modern radiotherapy, despite continued research and investigation over many years [1]. Methods of assessment of contouring
variation and possible solutions through education, automation
and intervention have been investigated extensively and reviewed
[1–3]. Variation in contouring has been attributed to; observer
experience [4], imaging modality [5,6], the use of guidelines [7],
and patient and tumor factors such as site, stage, age and size [8].
Spoelstra et al. [9] investigated the impact of contouring variation on dosimetry, showing that the introduction of a contouring
protocol signiﬁcantly reduced the risk of radiation-induced lung
toxicity. Other studies have shown that contouring variation can
have a signiﬁcant impact on dosimetry for head and neck, breast
and post-prostatectomy patients [10,11]. Vinod et al. [12] utilized
tumor control probability (TCP) in assessing the impact of incorporating F-18 ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) on non-small cell lung cancer (NSCLC) planning. They

demonstrated an impact of contouring variation on TCP ranging
from 1% to 24%.
Understanding the impact of contouring variation on TCP
would aid in development of contouring guidelines and adaptive
radiotherapy (ART) protocols. It would also assist in the design
of clinical trial protocols where contouring variation is a known
confounding factor [13,14]. At present, there is no consistent or
widely accepted method of contour comparison [1,2]. Fotina
et al. [2] investigated the relationships between different comparison metrics in an effort to recommend a minimum parameter set for ‘‘full description’’ of contouring variation. Ideally the
choice of metric should correlate with clinical outcome, as different tumor sites and planning techniques will differ in sensitivity
to delineation variability. The present study was designed to
investigate the relationship between contouring variation and
outcome surrogates speciﬁcally TCP, equivalent uniform dose
(EUD) and mean lung dose using a series of NSCLC patient datasets. The aim was to recommend geometric parameters for the
assessment of contouring variation, that relate to clinical
outcome.

⇑ Corresponding author. Address: Cancer Therapy Centre, Liverpool Hospital,
Locked Bag 7103, Liverpool, NSW 1871, Australia.
E-mail address: michael.jameson@sswahs.nsw.gov.au (M.G. Jameson).
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application was used to calculate volume, center of mass (COM)
location and maximal dimensions [X(med/lat), Y(ant/post) and
Z(sup/inf)] for each volume. The conformity index (CI) [1] was calculated for each observer volume and the GS volume:

Materials and methods
Patient datasets
Seven previously treated NSCLC patients were selected for the
study (Supplementary Table 1), ﬁve from a prior investigation [12]
and two additional. Free breathing CT scans were acquired with contrast using a Siemens Somatom™ (Siemens Medical Solutions,
Erlangen, Germany) system with 2 mm slice thickness and a
512  512 matrix. Diagnostic PET CT (dPETCT) scans were acquired
using a Phillips Gemini™ (Philips Healthcare, Best, Netherlands)
PETCT system. Radiotherapy planning PETCT (pPETCT) scans were
also acquired between 17 and 91 days after the dPETCT using the
same system with a ﬂat bed insert. Patients were injected with
400 MBq of FDG, rested 60 min for uptake in supine position before
image acquisition.

CI ¼

GS \ V i
GS [ V i

ð1Þ

where GS = gold standard and Vi = observer contour. A CI equal to
unity indicates perfect agreement while a CI of zero reﬂects no
overlap. The contours for each patient were treated as a single
group, representing the range of variation for analysis.
Radiobiological analysis and mean lung dose
Assuming the GS volume represented the true PTV, GS dose volume histograms (DVHs) were exported for plans generated based
on the observer volumes. The impact of observer variation on normal lung tissue was quantiﬁed with mean lung dose (MLD), as a
predictor for radiation pneumonitis [18]. The in-house developed
Comp Plan software [19] was used to calculate MLD and the following radiobiological metrics (see Supplementary Material for
details).

Delineation methods
Three radiation oncologists (observers A, B and C) experienced
in treating lung cancer contoured gross tumor volumes (GTVs)
based on the planning CT, dPETCT and pPETCT for each patient.
All contouring was completed using either Focal™ (Elekta Oncology Systems, Stockholm, Sweden) or Pinnacle3™ (Philips Healthcare, Best, Netherlands) treatment planning systems (TPSs). The
lung and mediastinal windows were initially set to W850 L-750
and W400 L20 but were allowed to be adjusted. A standard uptake
value (SUV) of 2.5 was used to visualize the primary on the dPETCT
and pPETCT. Nodes were contoured separately if not contiguous
with the primary otherwise, a single GTV was delineated. A uniform expansion of 8 mm clipped to bone was used to deﬁne the
clinical target volume (CTV) from GTV. The CTV to planning target
volume (PTV) margin was 15 mm craniocaudally and 10 mm
mediolaterally and was not allowed to be adjusted once created.

Statistics
Descriptive statistics were used to assess geometric and radiobiological variation. Spearman’s nonparametric rank-correlation
coefﬁcient (q) was used to quantify the association between geometric variation (volume, COM, dimension and CI) and radiobiological metrics (TCP, EUD and MLD) with a p value less than 0.05
considered signiﬁcant. SPSSÒ (SPSS Inc, Chicago, IL) software was
used for all statistical analysis.
In our study we have used 63 separate contours to investigate
the relationship between contouring variation and TCP/EUD, which
gives the power to detect q = 0.4, a = 0.05 (two sided) and 1-b = 0.9
[20] (see Supplementary Material for sample size calculation).

Reference ‘‘gold standard’’ volume
To assess geometric and dosimetric variation a ‘gold standard’
(GS) PTV was used. Assuming that the true tumor existed within
the observer contours a volume was created in the computerized
environment for radiation research (CERR) [15] with the simultaneous truth and performance level estimation (STAPLE) algorithm
using all observer contours [16].

Results
Fig. 1 shows the GS volume and observer contours in the axial
plane for cases 6 and 7. Cases 4 and 7 exhibited the largest variation in volume with mean contoured volumes of 867 ± 168 cm3
and 899 ± 419 cm3 (Table 1). The largest radiobiological variation
was also noted in cases 4 and 7. Both had involved mediastinal
nodes included in the GS volume which were not contoured by
all observers. As such the nodes were out-of-ﬁeld for some plans
resulting in mean GS EUDs of 53.6 ± 8.6 Gy and 43.6 ± 21.2 Gy.
While there was relatively large geometric variation in PTV contours for case 6 there is little variation in TCP and EUD. As the
tumor location was in the RLL the beam arrangement consisted
of anterior and posterior obliques. The majority of the contouring
variation was in the ant/post direction while the lateral variation
was minor, resulting in very little contouring variation in the
beams eye view.
Fig. 2 demonstrates the relationship between PTV volume and
MLD. While it is intuitive that larger PTV volumes will result in
higher MLD it was not strictly the case. The ﬁgure clearly shows
that variations in PTV volume of up to 500 cm3 can have very little
impact on MLD. This is because the MLD is also dependent on PTV
location, beam arrangement, lung size and technique.
Supplementary Fig. 1 shows the average difference in TCP when
analyzed by observer and imaging modality was generally less
than 0.1%, with standard deviation ranging 0.1–0.35%. The average difference in EUD for the PTV ranged from less than 1 Gy to
6 Gy. The average difference in MLD was less than 2 Gy for all

Treatment planning
For treatment planning the dPETCT and pPETCT were rigidly
registered to the planning CT by a senior dosimetrist and contours
copied to the planning CT. Ten conformal radiotherapy (CRT) treatment plans were generated per patient, one for each PTV (CT,
dPETCT and pPETCT) for each observer (A, B and C) and the STAPLE
volume using the Xio™ (Elekta Oncology Systems, Stockholm,
Sweden) TPS to give a total of 70 plans. All plans were generated
for a Siemens Oncor Impression linear accelerator with 1 cm leaves
(Siemens Medical Solutions, Erlangen, Germany) using a 2.5 mm
calculation grid. The originally treated CRT plan (3–5 conformal
beams) (Table 1) was projected on each PTV and modiﬁed to meet
International Commission on Radiation Units and Measurements
(ICRU) objectives for coverage and dose homogeneity by adjusting
beam apertures and weights [17]. Further planning goals limited
the volume of lung (excluding PTV) receiving 20 Gy to less than
35% (V20 6 35%) and the maximum spinal cord dose to 45 Gy.
Geometric analysis
All CT, structure and dose data were imported into CERR [15].
An in-house developed MATLAB (The Mathworks Inc, Natick, MA)
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Table 1
Variation in TCPlogit, TCPpossion, EUD and contouring metrics from GS reference volume between observers for all patients.
Patient

Stats

TCPlogit

EUD
(Gy)

TCPpossion

DCOM
(cm)

CI

Volume (cm3)

Dimension
X (cm)

Y (cm)

Z (cm)

1

Mean
SD

0.40
0.00

45.62
0.19

0.15
0.00

0.27
0.18

0.85
0.06

11.72
0.43

11.32
0.83

10.34
0.33

701.11
99.17

2

Mean
SD

0.63
0.01

60.48
1.02

0.43
0.02

0.92
0.47

0.76
0.09

8.46
1.68

10.21
1.54

8.41
1.17

349.98
92.44

3

Mean
SD

0.62
0.01

59.67
0.41

0.41
0.01

0.19
0.13

0.89
0.10

11.5
0.65

14.38
0.34

13.29
0.37

1019.14
129.6

4

Mean
SD

0.57
0.07

53.56
8.60

0.34
0.10

0.88
0.71

0.79
0.08

14.2
0.43

11.11
0.96

14.22
5.38

867.39
168.36

5

Mean
SD

0.64
0.00

60.79
0.09

0.44
0.00

0.21
0.11

0.90
0.03

10.49
0.29

11.21
0.71

10.28
0.43

622.31
38.64

6

Mean
SD

0.68
0.04

64.25
2.68

0.50
0.06

0.31
0.47

0.85
0.22

7.35
1.19

8.06
1.44

6.38
0.52

227.28
70.5

7

Mean
SD

0.44
0.22

43.60
21.17

0.24
0.16

0.96
0.49

0.67
0.20

12.12
2.76

11.66
1.49

14.4
2.55

899.29
418.7

Abbreviations: COV = center of volume; CI = conformity index; EUD = equivalent uniform dose; TCP = tumor control probability; SD = standard deviation.

Fig. 1. Coronal and axial CT images of observer (red lines) and STAPLE reference (gold lines) PTV contours for case #6 (left) and case #7 (right). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)

To investigate dependencies in the data Spearman’s q was also
analyzed with respect to the imaging modality and observer, these
results can be seen in Supplementary Table 2. What this shows is
that when the data are broken down by modality and observer
the metrics with the highest correlation are still XDim, ZDim and
Volume as in Table 2. The correlation values actually increase for
some metrics while maintaining statistical signiﬁcance. This is largely due to the fact that observer Z was a signiﬁcant outlier when
contouring on the PET scans.

observers and imaging modalities except for observer X which was
1 Gy, standard deviation ranged approximately 3.5–13 Gy.
Spearman’s q was calculated to investigate the relationship
between TCPlogit, TCPpossion, EUD and geometric variation for all
cases (Table 2). X and Z dimension demonstrated the highest correlation with average Spearman coefﬁcients of 0.49 (p < 0.01) and
0.48 (p < 0.01). DCOM and CI showed the weakest correlation with
average Spearman coefﬁcients of 0.25 and 0.31 (p < 0.05).

Discussion
While there have been studies quantifying the magnitude of
geometric contouring variation in NSCLC, investigations focusing
on the dosimetric impact and correlation remain sparse. Understanding the association between contouring variation and local
control for speciﬁc tumor sites and treatment techniques is highly
desirable. Here we present the ﬁrst study comparing the correlation of contouring metrics with modeled outcome, demonstrating
the link between geometric contouring variation and TCP for
NSCLC conformal radiotherapy.
The choice of reference volume to compare all other contours to
is contentious [21] and a source of uncertainty for this study. STAPLE was chosen as it reﬂects most probable volume based on the
observer volumes, other studies have used the most experienced
observer, consensus or average [1]. The rank from most to least
correlated geometric factor was in descending order X-Dim,
Z-Dim, volume, CI, DCOM and Y-Dim. The inter-model (TCP,
EUD) differences were small (<2%) and similar in magnitude. This

Fig. 2. Impact of variation in target volume on mean lung dose.
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Table 2
Spearman’s q for TCPlogit, EUD and TCPpossion and geometric variation for all patients.
Model

DCOM

Dimension

Volume

X

TCPlogit
EUD
TCPpossion

Y

CI

Z

q

sig.

q

sig.

q

sig.

q

sig.

q

sig.

q

sig.

0.25
0.25
0.24

0.05
0.05
0.06

0.48
0.51
0.48

0.00
0.00
0.00

0.22
0.24
0.24

0.08
0.06
0.06

0.46
0.51
0.46

0.00
0.00
0.00

0.42
0.45
0.42

0.00
0.00
0.00

0.32
0.31
0.31

0.01
0.02
0.02

Abbreviations: COM = center of mass; CI = conformity index; EUD = equivalent uniform dose; TCP = tumor control probability.

suggests that for NSCLC the relationship between geometric variation and radiobiology is not sensitive to the radiobiology model or
parameters used. This may not be the case for other sites where the
tumor response is less well known. This will likely vary based on
clinical site and technique.
One of the limitations of the current study is the number of
patients analyzed. Seven patients were assessed and may not be
representative of the NSCLC population. There were three observers that contoured each case three times, giving nine distinct PTV
volumes per case. It is possible that consistent over or under contouring by one observer may bias the results of the study. Also, it
has been demonstrated that different planning systems create
margins and interpret volumes of contours differently [22]. The
impact of this was minimized for this study by creating all margins
and plans in Xio. The conformal planning technique used may be
less sensitive to contouring variation than IMRT and VMAT for
example. Techniques with tighter margins would be more sensitive
to variation in delineation when assessed using this method. For
each treatment plan the DVH of the gold standard reference volume is analyzed, therefore, increasing the margins increases the
chance of irradiating the reference volume to a sufﬁcient dose for
tumor control, conversely smaller margins decrease this chance.
The trade off in these two scenarios is the amount of healthy lung
irradiated. Lütgendorf-Caucig et al. [23] evaluated COM displacements to estimate a PTV margin to ensure minimum CTV coverage
of 95% for 90% of patients using the margin recipe of van Herk et al.
[24]. Adopting this approach for inter-observer and intra-imaging
contouring variation a margin of 11 mm would be required based
on the data in this study.
The geometric parameters most closely related to outcome for
NSCLC were X-Dim, DCOM and CI. In a review of methods of analysis in contouring studies it was found that X-Dim was employed
in only 1/10 of the lung studies reviewed, while DCOM and CI were
used in 4/10 and 2/10 [1], and volume was the metric of choice in
8/10 studies. This highlights that the choice of metric for assessment of contouring variation is not driven by relevance to clinical
outcome but likely by the tools available to investigators. The
choice of metric will differ based on treatment site and technique.
Therefore, it is recommended that prior to conducting a contouring
study the most relevant metrics should be determined for the
given treatment site and planning technique. This knowledge combined with the minimum required set of geometric descriptors [2]
will ensure results of future contouring studies are consistent and
comparable.
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Supplementary Table 1 Patient characteristics
Patient
TNM
Histology
Prescribed dose (Gy/#) Primary location
1
T3N0M0
Undifferentiated NSCLC 45/25(PCT)
LUL
2
T2N0M0
SCC
60/30
LLL
3
T3N0M0
SCC
60/30
Left hilum
4
T1N3M0
Large cell carcinoma
60/30
Left hilum
5
T4N3M0
Large cell carcinoma
60/30
LUL
6
T1aN0M0
Large cell carcinoma
60/30
RLL
7
T2N2M0
Adenocarcinoma
60/30
RLL
Abbreviations: NSCLC = non small cell lung cancer; SCC = squamous cell carcinoma; PCT = Pancoast
tumor; LL = left lung; LLL = left lower lobe; LUL = left upper lobe; RLL = right lower lobe
Radiobiology calculations
Equivalent uniform dose (EUD) [1]:

1/𝑎

𝑣𝑖 𝐷𝑖𝑎

𝐸𝑈𝐷 =

(2)

𝑖

where vi = normalized volume for the voxel being considered, Di = the dose to the voxel being
considered and a is a parameter related to the structure being considered (a = -1 for PTVs [2]) that
drives the model.

TCP based on the logit model (TCPlogit)[3]

𝑣𝑖

𝑇𝐶𝑃𝑙𝑜𝑔𝑖𝑡 =

1
𝐷
1 + 50
𝐷𝑖

4𝛾 50

(3)
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where D50 = 51.24 Gy is the dose for 50% control, γ50 = 0.83 is the slope of the dose response curve
[4]

TCP based on Possion statistics (TCPpossion) [3]

1
𝑇𝐶𝑃 =
2

𝐷
𝑣𝑖 𝑒𝑥𝑝 𝑒𝛾50 (1− 𝑖 𝐷
50

(4)

where D50 = 64 Gy and γ50 = 1.3 [5]
Sample size calculation
In order to estimate the number of observations needed for the study, a sample size estimate is
required. The method described in Machin’s text book [6] was used, where for two normally
distributed variables it can be shown that:
1
1+𝜌
𝜌
𝑢𝜌 = log
+
2
1−𝜌
2 𝑁−1

(1)

In the above equation N is the sample size and ρ is the predicted correlation for significance level α
and power of 1-β, then:
𝑧1−𝛼 + 𝑧1−𝛽
𝑁=
𝑢𝜌 2

2

(2)

In order to calculate a value or N to substitute into equation (1) we can calculate an initial uρ
denoted 𝑢𝜌0 using:
1
1+𝜌
𝑢𝜌0 = log
2
1−𝜌

(3)

Machin [6] has tabulated results for which this process was repeated until the two consecutive
values of N were within unity (Table 1). From this table it can be seen that for ρ = 0.5, α = 0.05 (two
sided) and 1-β = 0.8 a sample size of 29 is needed. However, this is based on linear correlation (i.e.
Pearson) and in this study the non- parametric Spearman’s correlation was used. There is not a
straight forward method for calculating a sample size for Spearman’s ρ however Siegal states that
Spearman is about 91% as efficient as Pearson [7] therefore the sample size required for Spearman
is 32.
Page 2 of 6
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In our study we have used 63 separate contours to investigate the relationship between contouring
variation and TCP/EUD, which using the above table gives us the power to detect ρ = 0.4, α = 0.05
(two sided) and 1-β = 0.9.

Supplementary Table 2 Sample sizes for detecting a statistically significant correlation coefficient. Table
adapted from [1].
ρ

α

Power 1-β
0.8
0.9
782
1046
617
853
450
655

One-sided
0.025
0.05
0.10

Two-sided
0.05
0.10
0.20

0.2

0.025
0.05
0.10

0.05
0.10
0.20

193
153
112

258
211
162

0.3

0.025
0.05
0.10

0.05
0.10
0.20

84
67
50

112
92
71

0.4

0.025
0.05
0.10

0.05
0.10
0.20

46
37
28

61
50
39

0.5

0.025
0.05
0.10

0.05
0.10
0.20

29
23
18

37
31
24

0.6

0.025
0.05
0.10

0.05
0.10
0.20

19
16
12

25
21
16

0.7

0.025
0.05
0.10

0.05
0.10
0.20

13
11
9

17
14
12

0.8

0.025
0.05
0.10

0.05
0.10
0.20

10
8
7

12
10
8

0.9

0.025
0.05
0.10

0.05
0.10
0.20

7
6
5

8
7
6

0.1
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(C)

(E)

PTV

(B)

PTV

(D)

Lung

(F)

PTV

PTV

Lung

Supplementary Figure 1 TCP and EUD results for PTV (A-D) and V20, EUD and MLD results for lung (E
& F) grouped with respect to imaging modality and observer
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Supplementary Figure 2 Difference in TCP (A) and EUD (B) between STAPLE plan and observer plans for PTV and MLD (C) between the STAPLE plan and
observer plans for lung tissue (error bars indicate ± σ).
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a b s t r a c t
Purpose: To perform a comparative study assessing potential beneﬁts of endorectal-balloons (ERB) in
post-prostatectomy patients.
Method and materials: Ten retrospective post-prostatectomy patients treated without ERB and ten prospective patients treated with the ERB in situ were recruited. All patients received IMRT and IGRT using
kilovoltage cone-beam computed tomography (kVCBCT). kVCBCT datasets were registered to the planning dataset, recontoured and the original plan recalculated on the kVCBCTs to recreate anatomical conditions during treatment. The imaging, structure and dose data were imported into in-house software for
the assessment of geometric variation and cumulative equivalent uniform dose (EUD) in the two groups.
Results: The difference in location (DCOV) for the bladder between planning and each CBCT was similar
for each group. The range of mean DCOV for the rectum was 0.15–0.58 cm and 0.15–0.59 cm for the nonERB and ERB groups. For superior-CTV and inferior-CTV the difference between planned and delivered
D95% (mean ± SD) for the non-ERB group was 2.1 ± 6.0 Gy and 0.04 ± 0.20 Gy. While for the ERB group
the difference in D95% was 8.7 ± 12.6 Gy and 0.003 ± 0.104 Gy.
Conclusions: The use of ERBs in the post-prostatectomy setting did improve geometric reproducibility of
the target and surrounding normal tissues, however no improvement in dosimetric stability was
observed for the margins employed.
Ó 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 493–497

200 cm3 [3]. These day-to-day ﬂuctuations can have a substantial
dosimetric effect on both the prostate bed and the normal tissues
[2,3]. Daily imaging with registration to bony anatomy may not
be sufﬁcient in accounting for prostate bed motion. Relative to
bony anatomy, prostate bed displacement exceeded 5 mm in 21%
of treatments in the cranio–caudal (C–C) direction and 9% in the
anterior–posterior (A–P) for 20 patients [4].
Endorectal balloons (ERBs) have been used to stabilize the
internal anatomy for whole prostate treatment [5]. The ERB sits
within the rectum immobilizing the prostate and pushing parts
of the rectum out of the high dose region. ERBs reduced planned
anal wall and rectal wall doses when compared to no ERB [6].
While ERBs have been used in the PP setting [7], no study has
investigated inter-fraction geometric and dosimetric stability PP.
Two PP patient cohorts treated with or without ERB were used to
investigate organ motion and deformation over the treatment
course. Further, the delivered equivalent uniform dose for targets
and normal tissues was compared to planned equivalent uniform
dose (EUD) for both cohorts.

Adjuvant radiation therapy delivered post radical prostatectomy (PP) results in longer time to biochemical failure and improved
local control compared to watchful waiting [1]. Long-term followup of the EORTC 22911 trial concluded that there is a survival
beneﬁt associated with adjuvant radiation following surgery for
patients <70 years or having positive margins [1]. Intensity modulated radiation therapy (IMRT) is becoming the standard of care for
this patient cohort as it provides excellent target coverage and normal tissue sparing. However, precise daily localization and immobilization is required for accurate delivery of highly conformal
treatments.
Variation in prostate bed location day-to-day has been investigated previously [2–4]. Rectal volumes can vary signiﬁcantly
throughout treatment from 40 to +60% compared to planning
[3]. Similarly bladder variation can be major, varying up to
⇑ Corresponding author. Address: Cancer Therapy Centre, Liverpool Hospital,
Locked Bag 7103, Liverpool, NSW 1871, Australia.
E-mail address: michael.jameson@sswahs.nsw.gov.au (M.G. Jameson).
0167-8140/$ - see front matter Ó 2013 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.radonc.2013.08.024
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Methods
Patient data
Subsequent to ethics approval ten patients most recently treated with adjuvant radiotherapy following radical prostatectomy
were retrospectively selected as the non-ERB group for this pilot
study. A further ten patients were recruited prospectively after
radical prostatectomy to the ERB group (Supplementary Table 1).
The original planning CT was used for patients in the non-ERB
group. Two planning scans were obtained for the ERB group, one
without the ERB and one with the ERB in situ. QLRAD (QLRAD
B.V., Dalfsen, The Netherlands) ERBs were used in this study, details of which can be found elsewhere [5]. Images were acquired
with a Siemens Somatom™ (Siemens Medical Solutions, Erlangen,
Germany) system using 2 mm slice thickness and a 512  512 matrix. All patients were instructed to drink 500 mL of water prior to
simulation and treatment. Additional ﬁber supplements were initiated one week prior to simulation and continued throughout treatment. The image guided radiotherapy (IGRT) regimen consisted of
daily cone–beam CT (CBCT) fractions 1–5 and weekly thereafter.
All CBCTs were performed on a Synergy accelerator equipped with
XVI (Elekta Oncology Systems, Stockholm, Sweden) with 120 kVp,
1056 mAs using a 20 cm FOV and a bowtie ﬁlter.

of sacroiliac joint to superior border of pubic symphasis, inferior
rectum extended to a line drawn from the coccyx to the inferior
border of the pubic symphasis and the anus which extended another 4 cm. The inner wall of the rectum and anus was contoured
by contracting the outer wall contour by 5 mm [6].

Planning
All patients were planned with step and shoot IMRT, consisting of seven or nine non-opposing, coplanar ﬁelds using XioÒ
(Elekta Oncology Systems, Stockholm, Sweden). The prescribed
dose was 70 Gy and 64.4 Gy to the inferior and superior CTVs
respectively, delivered in 35 fractions. International Commission
on Radiation Units and Measurements (ICRU) objectives for coverage and dose homogeneity were adhered to [9]. Additional
planning goals limited the volume of rectum receiving 40 Gy to
less than 60% (V40 < 60%) and V60 < 40%. Further objectives limited V50 < 50% for bladder and V45 < 60% for femoral heads [10].
After registration and contouring, each patient’s original plan
was recalculated on all CBCTs. Due to the unstable CT numbers
of the non-scatter corrected CBCT images all relative electron
densities were forced to unity, except for ERBs which were set
to air [11]. For consistency in dosimetric comparison the planning CT was also density forced with the same values used for
the CBCTs.

Delineation
All planning and daily CBCT images were imported into Focal
(Elekta Oncology Systems, Stockholm, Sweden) for registration
and contouring. CBCT images were rigidly registered to planning
scans based on bony anatomy per standard IGRT practice on treatment. Target volumes and normal tissues were contoured on the
planning scan and all CBCTs for each patient (Fig. 1). The PP clinical
target volume (CTV) was delineated according to national consensus guidelines [8]. Brieﬂy, the inferior border of the CTV was
approximately 5 mm below the vesicourethral anastimosis covering all surgical clips. The inferior CTV (infCTV) was bounded by
the pubis symphysis, levator ani, obturator internus and anterior
rectal wall. Above the superior edge of the symphysis pubis the
superior CTV (supCTV) was extended cranially to include all of
the seminal vesical bed and the distal portion of the vas deferens.
A uniform CTV to planning target volume (PTV) margin of 10 mm
was used. The anterior border of the supCTV encompasses the posterior 15 mm of the bladder. Similarly the whole rectum was contoured in three sections: superior rectum from the inferior aspect

A

Geometric analysis
An in-house developed MATLAB (The Mathworks Inc., Natick,
MA) application in conjunction with the CERR platform [12] calculated volume and center of volume (COV) location. The conformity
index (CI) [13] was calculated for each CBCT volume and planned
volume, for the CTV, rectum and bladder volumes and subvolumes:

CI ¼

V planned \ V CBCTi
V planned [ V CBCTi

ð1Þ

where V planned and V CBCTi are the planning and ith CBCT contour volumes respectively. A CI equal to unity indicates perfect agreement
while a CI of zero reﬂects no overlap. The mean absolute surface distance (MASD) between planning and CBCT volumes was computed
as the average of all Euclidean surface distances per vertex from the
planning scan to each CBCT [14].

B

Fig. 1. Sagital views of targets and normal structures delineated for (A) non-ERB and (B) ERB groups. Blue: superior rectum; green: inferior rectum; red: anus; pink: superior
CTV and beige: inferior CTV.
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Dosimetric analysis

Geometric variation

EUD has been shown to be a useful tool when comparing complex radiotherapy plans [15]. The form suggested by Niermierko
[16] was used to evaluate the dose distributions for CTV, rectum
and bladder volumes and sub-volumes:

The mean ± SD CI for bladder was 0.54 ± 0.21 and 0.54 ± 0.20 for
the non-ERB and ERB groups, respectively (Supplementary Fig. 1).
Non-ERB/ERB CI values for the whole rectum, inferior rectum and
superior
rectum
were
0.50 ± 0.12/0.71 ± 0.07
(p < 0.01),
0.51 ± 0.12/0.78 ± 0.08 (p < 0.01) and 0.42 ± 0.13/0.59 ± 0.11
(p < 0.01). Similarly for the CTV, infCTV and supCTV the CI values
were 0.72 ± 0.15/0.73 ± 0.11 (p < 0.05), 0.87 ± 0.07/0.88 ± 0.05
(p < 0.01) and 0.54 ± 0.22/0.56 ± 0.15 (p = 0.1) for non-ERB/ERB.
The difference in location (DCOV) for the bladder between planning and each CBCT was similar for each group. The range of mean
DCOV for Whole rectum was 0.15–0.58 and 0.15–0.59 cm for the
non-ERB and ERB groups. However, the average change in Whole
rectum volume from planning for the non-ERB and ERB groups ranged from 84–224% and 98–120%. The infCTV DCOV for non-ERB
and ERB ranged from 0.01 to 0.05 and 0.02 to 0.14. The supCTV
range of average change in volume was 75–126% and 55–141%
for non-ERB and ERB respectively. The MASD is displayed in Supplementary Fig. 2 for non-ERB patient#8 and ERB patient#1 as representative cases.

EUD ¼

!1a
X
a
ðmi Di Þ

ð2Þ

i

where mi is the normalized volume for the voxel being considered, Di
is the dose to the voxel being considered and a is a parameter related to the structure being considered that drives the model. For
the current study a = 11.9 for the rectum [17], a = 8 for the bladder
[18] and a = 1 for the CTVs [18]. In-house software [19] was used
to calculate EUD and dose volume parameters V50 for bladder, V40
for rectum and D95 for CTV.
Statistics
The SPSSÒ (SPSS Inc., Chicago, IL) package was used for all statistical analysis. The two-sample Kolmogorov–Smirnov (K–S) test
was used to compare results between the non-ERB and ERB groups
[20]. Where a p value <0.05 would indicate that the geometric and
dosimetric distributions of the groups were statistically different.
Results
Patient data
For the non-ERB group 91 CBCTs were suitable for contouring
while 71 were suitable for planning. From the 10 patients recruited
to the ERB group, one patient (#10) had a superior non-ERB plan
and was treated without ERB and one patient had to cease ERB
use due to hemorrhoids. This left 70 CBCTs suitable for contouring
and 69 were able to be planned. Image artifacts and clipping were
the leading reasons why some CBCT datasets could not be contoured or planned.

Inter-fraction dosimetric stability
Fig. 2 shows variation in V40 from planning value over the
course of treatment for Superior rectum and Inferior rectum. For
supCTV and infCTV the difference (mean ± SD) in D95% for the
non-ERB group was 2.1 ± 6.0 Gy and 0.04 ± 0.20 Gy. While for
the ERB group the difference in D95% was 8.7 ± 12.6 Gy and
0.003 ± 0.104 Gy from the supCTV and infCTV. The difference in
bladder V50 from planned was 20.9 ± 23.5% for the non-ERB group
and 12.6 ± 22.1% for the ERB group. Fig. 3 depicts the difference between the planned and delivered EUD.
Discussion
This study represents the ﬁrst comparison of inter-fraction organ deformation and dosimetric stability for patients treated with

Fig. 2. Plots of the difference in V40 for superior (A) and inferior (B) rectum with no ERB (left column) and ERB (right column) red line indicates ideal situation of no variation.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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is required to appreciate the potential beneﬁt of ERBs in the post
prostatectomy setting.
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Appendix A. Supplementary data
Fig. 3. Difference between planned EUD and average delivered EUD for a number of
organs and sub-organs for each group, error bars indicate one standard deviation.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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or without ERB in the post-prostatectomy setting. The ERB improved the CI of the Whole rectum, Superior rectum and Inferior
rectum by 21%, 27% and 17% (p < 0.01). The improved geometric
stability with the ERB did not translate into a statistically signiﬁcant beneﬁt in inter-fraction dosimetric stability based on DEUD.
The reduced dosimetric stability seen for the bladder and supCTV
is likely due to bladder ﬁlling and slight differences in ERB insertion depth between fractions.
The range of non-ERB organ motion was similar to those reported in other studies [21]. A study on the use of gold seed ﬁducials in PP radiotherapy reported slightly larger inter-fraction
infCTV
motion
of
0.03 ± 0.09 cm,
0.4 ± 2.4 mm
and
0.11 ± 0.21 cm in the LR, SI and AP directions [22]. Compared to
DCOV in this study of 0.01–0.05 cm, these differences are likely
due to the different methods of motion measurement used.
While the affects of the ERB on dosimetric stability were insigniﬁcant on average for the ERB cohort, there were indications that
the ERB may be beneﬁcial for some patients. However, it is difﬁcult
to know whether these patients would have been stable if treated
without ERB. For example, patients in each group had single fraction variations between planned and delivered dosimetry that
was deemed clinically signiﬁcant by the treating physician. As reported elsewhere, the cumulative effect of per treatment differences is reduced signiﬁcantly with fractionation [23].
Limitations in this study include the inherent uncertainty in contouring anatomical structures, which was minimized by having a single observer contour all structures in each group. The same window
and level settings were used for all patients when contouring ERB on
the CBCT scans. This minimized variation in deﬁning the ERB lumen/
tissue boundary. The dosimetric advantages of ERBs are affected by
the differences in the original plan dosimetry, as well as inter-fraction and intra-fraction variations. In a planning comparison study
Smeenk et al. reported a signiﬁcant improvement in rectum V40 for
the ERB versus non ERB group [6]. A recent study demonstrated reduced intra-fraction target motion with ERB for deﬁnitive prostate
[24]. The choice of CTV to PTV margins inﬂuences the dosimetry analysis since larger margins will result in the CTV dosimetry being less
sensitive to geometric instability [25]. Further investigation with a
larger study is required to establish accurate margins and conﬁrm
the overall advantages of ERB in PP radiotherapy.

[1] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical
prostatectomy for high-risk prostate cancer: long-term results of a randomised
controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
[2] Fiorino C, Foppiano F, Franzone P, et al. Rectal and bladder motion during
conformal radiotherapy after radical prostatectomy. Radiother Oncol
2005;74:187–95.
[3] Haworth A, Paneghel A, Herschtal A, et al. Veriﬁcation of target position in the
post-prostatectomy cancer patient using cone beam CT. J Med Imaging Radiat
Oncol 2009;53:212–20.
[4] Klayton T, Price R, Buyyounouski MK, et al. Prostate bed motion during
intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys
2012;84:130–36.
[5] Smeenk RJ, Teh BS, Butler EB, van Lin ENJ, Kaanders JHAM. Is there a role for
endorectal balloons in prostate radiotherapy? A systematic review. Radiother
Oncol 2010;95:277–82.
[6] Smeenk RJ, van Lin ENJ, van Kollenburg P, et al. Endorectal balloon reduces
anorectal doses in post-prostatectomy intensity-modulated radiotherapy.
Radiother Oncol 2011;101:465–70.
[7] Teh BS, Mai W-Y, Augspurger ME, et al. Intensity modulated radiation therapy
(IMRT) following prostatectomy: more favorable acute genitourinary toxicity
proﬁle compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol
Phys 2001;49:465–72.
[8] Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation
therapy: consensus guidelines of the Australian and New Zealand Radiation
Oncology Genito-urinary group. Radiother Oncol 2008;88:10–9.
[9] Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology
2007;242:360–85 [Review] [267 refs].
[10] Trans Tasman Radiation Oncology Group: RAVES – radiotherapy adjuvant
versus early salvage a Phase III multi-centre randomised trial comparing
adjuvant radiotherapy (RT) with early salvage RT in patients with positive
margins or extraprostatic disease following radical prostatectomy (TROG
08.03) – Protocol. 2008.
[11] Jain P, Marchant T, Green M, et al. Inter-fraction motion and dosimetric
consequences during breast intensity-modulated radiotherapy (IMRT).
Radiother Oncol 2009;90:93–8.
[12] Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for
radiotherapy research. Med Phys 2003;30:979.
[13] Jameson MG, Holloway LC, Vial PJ, Vinod SK, Metcalfe PE. A review of methods
of analysis in contouring studies for radiation oncology. J Med Imaging Radiat
Oncol 2010;54:401–10.
[14] Dowling J, Fripp J, Chandra S, et al. Fast automatic multi-atlas segmentation of
the prostate from 3D MR images. Prostate Cancer Imaging: Image Anal ImageGuided Interventions 2011:10–21.
[15] O’Daniel JC, Garden AS, Schwartz DL, et al. Parotid gland dose in intensitymodulated radiotherapy for head and neck cancer: is what you plan what you
get? Int J Radiat Oncol Biol Phys 2007;69:1290–6.
[16] Niemierko A. Reporting and analyzing dose distributions: a concept of
equivalent uniform dose. Med Phys 1997;24:103.
[17] Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose–volume
effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys
2010;76:S123–9.
[18] Wu Q, Mohan R, Niemierko A, Schmidt-Ullrich R. Optimization of intensitymodulated radiotherapy plans based on the equivalent uniform dose. Int J
Radiat Oncol Biol Phys 2002;52:224–35.
[19] Holloway LC, Miller JA, Kumar S, Whelan BM, Vinod SK. Comp Plan: a
computer program to generate dose and radiobiological metrics from dose–
volume histogram ﬁles. Med Dosim 2012;37:305–9.
[20] Wang KK-H, Vapiwala N, Deville C, et al. A study to quantify the effectiveness
of daily endorectal balloon for prostate intrafraction motion management. Int J
Radiat Oncol Biol Phys 2012;83:1055–63.

Conclusion
The use of ERBs in the post prostatectomy setting improved
geometric reproducibility of target volumes and surrounding normal tissues. Improvements in dosimetric stability were inconclusive. A larger study incorporating inter- and intra-fraction motion
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Supplementary Material
Supplementary Table 1 Summary of patient characteristics for each group
Non-ERB group ERB group
Age (years)
Median
64
64
Range
52-74
52-72
Time from surgery to RT (months)
Median
7.9
24.4
Range
2.6-99.4
3-75.7
Pre-RT PSA (ng/mL)
Median
0.12
0.07
Range
0.03-0.26
0.04-0.21
Gleason Score (n)
6
0
1
7
6
6
8
2
1
9
2
2
Pathology (n)
pT1
1
0
pT2
3
6
pT3
6
4
Extracapsular extension (n)
Yes
8
4
No
2
6
Surgical margin
Positive
8
5
Negative
2
5
Abbreviations: ERB = Endorectal balloon; RT = radiation therapy; PSA = prostate specific antigen
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Supplementary Material

Supplementary Fig 1. Distribution of conformity index results for various organs and sub organs for
non-ERB and ERB groups.
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Supplementary Material

Supplementary Fig 2. Posterior (top row) and anterior (bottom row) views of 3D CTV for no ERB
(left column, case#8) and ERB (right column, case#1) with mean Euclidean distance from planning
scan to CBCT represented by color.
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Chapter 7: Superior target volume and organ stability with
the use of endorectal balloons in post-prostatectomy
radiotherapy
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Abstract
Background and purpose: Phase three clinical trials are powered based on an estimate
of the treatment benefit differential between the standard and experimental arms. The
accuracy of radiotherapy contouring may impact on the ability to distinguish between
treatment arms. This study aims to model the effect of contouring variation on tumour
control probability (TCP) and consequently on clinical trial sample size.
Material and methods: All Australasian observers participating in the PORTEC-3 trial
were sent a de-identified CT of a female pelvis on which to contour relevant target
structures and normal tissues. Each observer’s contours were analysed using in-house
code in conjunction with CERR in Matlab®. A “gold standard” consensus target was
created by the trial review committee. Geometric analysis consisted of volume, centre
of mass (COM), and DICE similarity coefficient with the “gold standard” consensus as a
reference. Four-field-box, conformal and intensity modulated treatment plans were
generated for each observer set of contours. A standard radiobiological model was used
to estimate TCP for each plan calculated onto the “gold standard” contours. The
uncertainty in trial sample size was calculated using standard statistical methods.
Results: The variation range in CTV volume, COM, and DICE similarity coefficient across
observers was 293 cm3, 0.29 – 2.7 cm, and 0.49 – 0.98 in relation to the “gold standard”
respectively. The mean (± σ) variation in TCP compared to the “gold standard” was 0.29 ± 0.45%, 0.66 ± 0.52%, and 0.18 ± 0.63% for the four field, conformal, and IMRT
plans respectively. A 0.29% decrease in TCP lead to a required increase of 3 (642 to
645) patients to maintain the same statistical power. For the worst case of a 1.63%
decrease seen in one of the four field plans an extra 19 (642 to 661) patients would be
required.
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Conclusions: The variation seen in contour definition resulted in a sample size
uncertainty of 1.4-2.4%. Radiotherapy clinical trials usually include quality assurance
(QA) to ensure contouring variation is limited to an acceptable level. The method
reported here could be applied to the results of such QA to improve or verify the
accuracy of sample size and power calculations for future RT trials.

Introduction
The randomised controlled trial (RCT) is the most effective means available to answer
questions about treatment effectiveness when designed, conducted and reported
appropriately

[1].

It is well recognised that robust methodology and quality assurance

(QA) is required to ensure the validity of RCTs [2]. There are two types of error that trial
designers go to great lengths to avoid: Type I and II errors, these are described in detail
by Bentzen

[3].

Briefly, Type I errors are false positives (treatment A is found to be

superior to treatment B when, in fact, it is not) and Type II errors are false negatives
(treatment A is found to be no better than treatment B when, in fact, it is), see Table 1.
In a retrospective review of clinical trial benchmarking and case review initiatives,
Fairchild et al demonstrated that QA measures should ensure optimal radiotherapy
delivery [4]. There are currently efforts underway to harmonise QA initiatives amongst
cooperative groups, one such endeavour is the homogeny of clinical trial groups QA
standards [5].

Consistency of contouring according to protocol has been investigated for a number of
RCTs

[6-10].

The accuracy and consistency of contouring in a RCT may be affected by

heterogeneity within contributing institutions technology and experience

[11].
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Poortmans et al

[12]

calculated the effect of variation in planning on the projected

survival for the EORTC 22922/10925 advanced breast cancer RCT. A reduction in
projected overall survival from 5% to 3.8% at ten years was estimated due to
suboptimal dose distributions collected using a benchmarking case. Pettersen et al

[13]

modelled the impact of dosimetric uncertainty on sample size for RCTs and showed
that reduced uncertainty in dose resulted in a significant reduction in required patient
numbers. Dosimetric uncertainty is influenced by contouring variation and has been
demonstrated to be significant for a number of clinical sites

[14-16].

Thus contouring

variation may impact on clinical trial outcomes and should be considered in trial
design.

Table 1 Description of type I and II errors in clinical trials

Reality
Treatment A ≠ B

Treatment A = B
Error (Type I)

Research

p < 0.5

Correct result

False positive

Error (Type II)
p > 0.5

Correct decision
False negative

PORTEC-3 is a recently closed RCT comparing concurrent chemo-radiation and
adjuvant chemotherapy verse pelvic radiation alone in high risk and advanced stage
endometrial carcinoma

[17].

The radiotherapy component of this RCT required

investigators to delineate a number of target structures in the pelvis that were not
typically contoured in Australasian centres at the time of recruitment commencement.
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Therefore a decision was taken by the Trans-Tasman Oncology Group (TROG) to
perform a bench marking exercise to assess contouring consistency amongst
Australasian clinicians.
To date there has been no attempt in the literature to incorporate the findings of a
benchmarking exercise into the sample size calculation of RCTs to account for the
variation in delineation or planning. This paper presents novel methodology for
undertaking this, utilising data from the PORTEC-3 benchmarking exercise. The results
of the benchmarking study and associated methodology have been presented.
Incorporation of the contouring variation observed in the PORTEC-3 benchmarking
study into the RCT sample size calculation is presented in the current study.

Methods
The proposed methodology is described in Fig. 1. and consists of three main stages. The
first is the assessment of contouring variation using data from the PORTEC-3
benchmarking exercise. The second involves analysing the impact of the contouring
variation on dosimetry, this required the generation of treatment plans for the
benchmarking contours. Unlike a benchmarking study the treatment plans (four field
box, 4FLD box; conformal, 3DCRT; intensity modulated, IMRT) were generated by two
investigators (MJ and JM), see section 2.2. Dosimetric variation was assessed using
physical dose volume histograms (DVH) to calculate tumour control probability (TCP).
The third stage consisted of incorporating the modelled variation into the RCT sample
size calculation as uncertainty in the survival rates of the standard and experimental
arms.
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Fig. 1. Flow chart with decision points describing the proposed methodology for assessing
the impact of contouring variation in RCT design (modified from Nelms [18, 19]).

1.1.1 Target delineation
Participating observers were asked to contour a test case according to trial protocol,
where multiple observers from single institutions would be contributing patients, each
individual observer took part. Contouring consisted of the CTV including the upper
50% of the vagina, the vaginal tissues superior to the vaginal marker, the paravaginal /
parametrial soft tissues, and the distal common, external, and internal iliac lymph node
regions. Inclusion of the sub-aortic pre-sacral nodes was recommended for tumours
with involvement of the cervix. A margin of 7-10 mm was to be used from CTV to PTV
with a margin of 12 mm in the upper vaginal region to account for bladder and rectal
filling. “gold standard” reference volumes were created for comparison of observer
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contours, these consisted of consensus target and organ at risk (OAR) volumes
delineated by the local trial coordinators.

1.1.2 Treatment planning
Treatment plans were then generated using the Pinnacle3® v9.0 (Philips Medical
Systems, Nederland B.V. Best, The Netherlands) treatment planning system (TPS). The
Adaptive Convolve algorithm was employed with a dose grid of 3 mm3. The sensitivity
of planning technique to contouring variation was assessed by generating three
different plans for all benchmarking and “gold standard” contours; 1) a 4FLD box using
10 MV photons with AP, PA and lateral beams, 2) a 3DCRT plan using seven 10 MV
photon beams and 3) a 10 MV IMRT plan using “gold standard” OAR volumes in the
optimization process as normal tissues were not delineated by all participating
institutions.

1.1.3 Geometric variation
All available observer’s contours were collated onto a single CT with the “gold
standard” contours. This was loaded into CERR

[20]

and an in-house

[15]

developed

MATLAB® (The Mathworks Inc, Natick, MA 2009) script was used to analyse each
observer’s target volumes. The volume and centre of mass (COM) of each observer’s
CTV contour was assessed. To quantify the variation with respect to the “gold standard”
target the DICE similarity coefficient (DSC) was used

[21].

For each observers’ target

volume, A, and the gold target volume, B, the DSC is defined as:

( ⋂ )
(
)

(1)
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A DSC equal to zero indicates that the two volumes do not overlap at all, while a DSC
equal to one indicates perfect overlap.

1.1.4 Tumour Control Probability (TCP)
To assess the impact of contouring variation on TCP the “gold standard” target volume
was assumed to be the true target. Treatment plans were developed as described in
section 2.2 for each observer’s target. The TCP calculated for the “gold standard” target
volume. CTV DVHs were used to calculate TCP using the Comp Plan program [22].

∏

(2)
[

(

)

]

The logit model (equation 2) was used, where the dose to achieve 50% control is TCD50,
the slope of dose response curve is γ50, the normalized volume is vi and the dose to the
voxel being considered is Di. Parameters were chosen as the mean values from multiple
institution adjuvant radiotherapy cohorts as reported by Okunieff et al [23] with TCD50 of
30.80 Gy, and a γ50 of 0.40 %/%. To assess any bias introduced by choice of model and
parameters these calculations were repeated with a number of published models and
data, see supplementary Fig. 1.
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1.1.5 Statistical Considerations
The baseline number of required patients was calculated assuming an exponential
survival curve. With a false positive error rate of 5% (α = 0.05), a power of 80% (1 – β =
0.80) assuming equal patient numbers in each arm (p = 0.50). An accrual period of 5
years and follow up of 2.5 years was used to detect a 10% difference in 5-year overall
survival (OS) with the standard arm having OS of 65-75% [17]. The minimum number of
patients required in the PORTEC-3 protocol was 655 with a target of 670 and the final
number included at close was 686.

The variation in TCP due to contouring uncertainty obtained from the PORTEC-3
benchmarking exercise was then incorporated into the power calculation as
uncertainties in the OS rates for each arm. These uncertainties were applied to both
arms equally as patients were randomized.

The sample size calculation was based on a parallel fixed sample size clinical trial with
survival as the main endpoint

[17].

First the number of events (i.e. deaths) to be

observed is calculated:
(

)

⁄

(

)

(3)

( )

Where D is the number of deaths, p is the allocation ratio (i.e. 0.5 for a 1:1 allocation), δ
is the hazard ratio δ = log(RN)/log(RS) where, RN and RS are the survival rates in the new
and standard arms. The Z1-α/2 and Z1-β values represent area under the normal
distribution related to the significance level and statistical power respectively. Once the
number of deaths (equation 4) required is known the number of patients, N, can be
estimated.
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̅

(
Where

(

)

(4)

)

is the accrual rate which is assumed to be known,

is the length of follow up

from the end of accrual, is the time at which ̅ is estimated, a the accrual duration is
then chosen to give the number of deaths required by Equation (4). Hence the number
of patients N = ra. To assess the impact of choice of sample size calculation technique a
number of difference methods were evaluated and compared in Supplementary Fig. 2.

Results
At the time of analysis, of the 31 datasets distributed to Australasian centres one
dataset was missing, two were in non DICOM format, five were corrupt and not able to
be imported into Pinnacle3®, and five of the datasets were exact copies of other
submissions from the same institution (presumably reviewed by the contributing
observer). This left 18 distinct datasets available for analysis as part of this study. The
contours analysed as part of this study are displayed in Fig. 2.

1.1.6 Geometric variation
Variation in volume of the contoured target is illustrated in Fig. 3 A). The whiskers
represent the minimum and maximum values while the box shows the 2 nd and 3rd
quartiles. The mean contoured CTV volume was 398.9 cm3 (range: 228.4 – 521.4 cm3).
The distance between COM (∆COM) of the “gold standard” and each contoured target is
shown in Fig. 3 A). Most ∆COM were less than 2.0 cm with a mean of 1.4 cm (range: 0.3
– 2.7 cm). The mean DSC for the CTV was 0.73 (range: 0.49 – 0.98). The observer CTV
volume with the highest CI also had the lowest ∆COM.
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Fig. 2. Axial, sagittal and coronal slice through the pelvis showing variation in PTV
definition
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B

A

Fig. 3. Box and whisker plots representing the variation in A) variation in DSC and COM
and normalized volume relative to the “gold standard” reference volume and B) the
variation in TCP as calculated on the “gold standard” reference for each planning
technique

1.1.7 Tumour Control Probability
The variation in TCP for each participating centre per planning technique is presented
in Fig.3 B) and Table 2. There was a significant difference in mean TCP variation
between IMRT 67.1% (σ = 0.6%) and 4FLD 66.3% (σ = 0.5%; p < 0.01), and 3DCRT
66.6% (σ = 0.5%) and IMRT (p < 0.01), but there was no significant difference between
3DCRT and 4FLD (p = 0.25). The TCP of the “gold standard” target volume and plan
was 66.9% for the IMRT and 66.7% for the 4FLD box while the 3DCRT plan was 65.9%.
In comparison to the 4FLD box plan, the IMRT and 3DCRT plans resulted in reduced
small bowel dose.
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Table 2 Difference in TCP from baseline value calculated for “gold standard” reference
volume specific plan
4FLD
Mean -0.29%
σ
Max

0.45%

3DCRT

IMRT

0.66%

0.18%

0.52%

0.63%

-1.63% -0.34% 1.18%

1.1.8 Sample Size
Table 3 summarises the effect of the TCP variation on the sample size calculation. Using
the original survival estimates for the standard and experimental arm the sample size
estimate was 642 patients. If the systematic and random TCP variation from the “gold
standard” is included for the 4FLD, 3DCRT, and IMRT planning techniques the sample
size estimate is 645 (σ = 9), 633 (σ = 13) and 639 (σ = 16) respectively.
Table 3 Sample size calculations for reference and incorporating contouring variation
assessed in the PORTEC-3 benchmarking study
Control rate
Experimental
Sample
size

Planned

(%)

rate (%)

estimate

65

75

642

74.71
4FLD

64.71 (σ = 0.45)

65.66 (σ = 0.52)

65.18 (σ = 0.63)

645 (σ = 9)
(σ

=

0.52)
75.18

IMRT

=

0.45)
75.66

3DCRT

(σ

0.63)

633 (σ = 13)
(σ

=
639 (σ = 16)
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The relationship between control in the standard (with corresponding assumptions
from section 2.5) and the required sample size is displayed in Fig. 4 with the baseline
sample size marked in red and the mean (solid) ± σ (dashed) for 4FLD marked in green.
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Fig. 4. Plot showing relationship between control rate and sample size. Obtained by
varying the survival rate and keeping the risk differential at 10%. Red line indicates
baseline sample size and green represents mean (solid) ± σ (dashed) sample size for 4FLD
technique taking contouring variation into account

1.1.9 Discussion
Clinical trials should be conducted with robust methodology and QA. In trials that
include radiotherapy it has been shown that as the heterogeneity of the radiotherapy in
a trial goes up, so too does the number of patients needed to detect a significant
treatment differential

[3].

Thus, it is in the best interest of the trial investigators to

minimize the heterogeneity in delivered radiotherapy. One of the largest contributing
factors to treatment heterogeneity in radiotherapy is contouring variation [9].
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There are a number approaches to minimizing contouring variation in RCTs involving
radiotherapy, these QA measures have been reviewed by Webber et al
site credentialing

[25]

[24].

Level 1 is

whereby a site that is contributing patients to a trial(s) is

credentialed by an outside body. This usually involves a facility questionnaire and a
dosimetry audit. Level 2 is the bench marking exercise [12] in which an example case is
sent to institutions that are interested in contributing patients to a trial. These
institutions generally contour and/or plan this case according to trial protocol and the
results are made available to the institution. Levels 3 and 4 consist of individual case
review

[26],

where either limited selected RCT cases (level 3) or an extensive number

(level 4) are reviewed by the RCT committee or other QA group. The results of the
independent case review are then provided to the participating institutions. Level 5 is a
complex dosimetry check consisting of generating a protocol specific plan on a physical
phantom, irradiating the phantom and having results reviewed by an independent
team. Many trials use a combination of these approaches to assess institutions when
contributing patients to a RCT.

In the current study the results of the ANZGOG/TROG initiated PORTEC-3
benchmarking study have been incorporated into a RCT sample size calculation. For the
reference conditions used, the number of patients required was not significantly
affected by the variation in contouring observed. This can be attributed to the
contouring variation observed not being substantial given the very large target volume.
Additionally, due the location of the target volume (medial) the dosimetry was
relatively insensitive to contouring variation. Observer’s tended to over rather than
under contour, resulting in adequate coverage of the “gold standard” reference CTV,
however potential over exposure of OARs (e.g. small bowel and bladder). The largest
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variation in TCP was observed for the IMRT technique, this was as expected as the
more conformal the dose distribution the greater the sensitivity to contouring
variation.

The amount of contouring variation may have been larger than if the benchmarking
study was run later in the trial. As observers contribute patients to a trial over time
they become more familiar with the protocol which may reduce the amount of
contouring variation [4]. As this was an ANZGOG/TROG initiated benchmarking study
(i.e. not general QA) all of the observers were from Australian and New Zealand
centres and therefore may not be representative of the wider international group
contributing patients to the trial. The benchmarking study only consisted of one patient
data set and contouring variation may be influenced by patient specific parameters. For
example, unusual anatomy and poor image quality due to patient size. Also, the
benchmarking patient was stage IIA grade 3 and the PORTEC-3 trial allows for a variety
of high risk and advanced stage stratifications [17].
There are a number of uncertainties and potential bias associated with this type of
analysis. These relate to radiobiological modelling of TCP with respect to
model/parameter choice, sample size calculation methods employed, and the
assumptions on which they are based. These have been assessed in the supplementary
material section and potential impacts stated above. Due to the limited availability of
TCP model parameters for some tumour sites and differences in underlying statistical
assumptions used, uncertainty and bias analysis should be performed for each trial
protocol when the methodology proposed in this work is employed Fig. 1.
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The sample size calculation method used was based on the TROG statistical guidelines
and was compared to other techniques (see supplementary Fig. 2.). For the
assumptions made (0.65 control rate with 10% risk difference, see 2.5 Statistical
Considerations) the spread among the different calculation techniques was
approximately 40 patients. Although this variance seems large the gradient of each of
the techniques in supplementary Fig. 2. is approximately equal at a control rate of 0.65.
Therefore, the reported difference in sample size from baseline will be equal for each
technique. Ideally statistical design of clinical trials would model the incorporation of
uncertainties involved in the parameters used. The final number of patients included in
PORTEC-3 was 686, 16 more than the planned target of 670 with a minimum
requirement of 655. The minimum number required differs from the 642 calculated in
above, this is likely due the use of a different method of calculation (see Supplementary
Fig.2.).

In this study local control (TCP) in the adjuvant setting was modelled as a surrogate for
overall survival as used in a sample size calculation. Although there is no data on the
link between TCP and overall survival for endometrial carcinoma one of the aims in
controlling local disease is the prevention of metastatic spread. In a retrospective
analysis of high risk patients (stage IC, grade 3) registered but not eligible for the
original PORTEC-1 trial, local relapse rates for adjuvant RT alone were 13%, while the
rates of distant metastases and overall survival were 31% and 74% at 5 years [27]. In the
combined modality setting Greven et al reported the results of adjuvant radiotherapy
combined with cisplatin/paclitaxel chemotherapy

[28].

The four-year recurrence rates

were 2%, and 19% for pelvic regional and distant disease. Furthermore, overall
survival and disease free survival at four years was 85% and 81% respectively.
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For the purpose of the sample size calculations, TCP uncertainty due to contouring
variation was assumed to be equal in both arms however only the experimental arm
received chemotherapy. Therefore the effect on TCP of contouring variation may be
differential as chemotherapy will shift the dose response curve [29, 30]. Additionally, TCP
uncertainty due to contouring variation may mask the benefit of combined modality
regimens and can impact on overall survival

[9].

This differential effect depending on

treatment arm may change the assumed risk difference (10% for PORTEC-3) between
the two arms and hence may have a large impact on sample size. For example, a 1%
decrease in risk differential (from 10% to 9%) equates to an additional 160 (80 in each
arm) patients required to maintain 1 – β = 0.80.

There will likely also be contouring variation in any previous studies on which the trial
in question was based thus, one might argue that the impact of contouring variation is
already taken into account in the randomization process. Nevertheless, the contouring
variation or the impact of this contouring variation is likely to vary between the
previous studies and the study in question. Typically the number of clinicians
contributing to RCTs is larger than the pilot studies on which they are based increasing
the probability of inter-observer variation due lack of familiarisation with technique,
and small patient numbers treated at contributing sites

[9].

Moreover, radiotherapy

treatment and planning technology changes over time. This change in technology might
be explicit due to new techniques (e.g 3DCRT to IMRT), images used for contouring (e.g.
CT to MRI based planning), or less obvious due to changes in planning tools and image
quality [31].

The current study employed two planners to complete the treatment plans using
contours from the contributing observers, this was to enable the comparison of 4FLD,
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3DCRT and IMRT techniques. In reality, a large clinical trial would contain planning
variation, possibly increasing the impact on sample size.

In a modelling study, Pettersen et al demonstrated that as the uncertainty in delivered
dose increases, the required sample size to answer a clinical question to a given power
increases

[13].

Poortmans et al reported the results of a benchmarking study from the

EORTC 22922/10925 protocol and claimed that the dosimetric variation observed may
lead to a falsely non-significant result, fortunately this was not the case

[32, 33].

Both of

these studies advocate for rigorous QA and dosimetry credentialing of centres before
contributing to RCTs. Previous work has shown that geometric contouring variation is
significantly correlated with variation in TCP [15]. While a number studies have assessed
contouring variation with benchmarking datasets [4] this is the first to assess the impact
of that variation on the sample size calculation.

Conclusion
A methodology for the incorporation of contouring uncertainty available through
preclinical trial QA to assess necessary sample size has been proposed and tested using
data available from the PORTEC-3 ANZGOG/TROG benchmarking exercise. It was
demonstrated that contouring variation can result in an increase in required sample
size. The impact of contouring variation on sample size varies with respect to the
sample size calculation method and the treatment technique. Consequently, this type of
assessment should be performed in the initial protocol development stage of
radiotherapy RCTs. It is of particular importance in combined modality trials where the
impact of the contouring variation may differ depending on the arm of the trial.
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Supplementary Material
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Supplementary Fig. 5. Radiobiological model and parameter uncertainty analysis. Figures A), B) and C) show 3D mesh of TCP values for corresponding
TCD50 and gamma50 parameters. As can be seen from the figures the probit model consistently returns higher TCP values except for larger TCD50 where
the logit is higher for IMRT and 4FLD and the possion for 3DCRT. These were calculated using the model and parameter values listed in D) [22, 34].
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Supplementary Fig. 6. Sample size calculated using the TROG guidelines [35], Binomial [36],
Pocock [37], Kelsy, Fleiss and Fleiss with continuity correction [38]. Assuming a 10% risk
differential between the standard and experimental arms. Red vertical and horizontal
lines indicate standard arm survival and corresponding sample size estimate from
PORTEC3 protocol.
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Chapter 10: Discussion and conclusions
10.1 General discussion
Despite much advancement in the techniques and technology associated with
radiotherapy treatment planning and delivery, there are a number of aspects
that still present challenges and require further research. Accurate and precise
delineation of targets and normal tissues is still one of the largest uncertainties
in the radiotherapy planning chain[1]. One of the shortcomings of the contouring
study literature is the lack of consensus on metrics of comparison of contours[2],
the result of which is the inability to compare results between studies. Chapter 4
addresses this problem by presenting a framework for establishing the most
significant metrics of variation for particular treatment sites and techniques.
This, combined with a minimum set of metrics[2] and appropriate statistical
presentation should allow for the inter-comparison of contouring studies in the
future.

There has been considerable effort devoted to the development of robust
automatic treatment planning techniques but these are yet to become
widespread[3,

4].

The results of chapter 5 demonstrate that plan quality

decreased with decreasing planner experience, and, the efficiency of plan
delivery also increased with increasing planner experience. These results could
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be seen as an example as to why automated inverse planning techniques
warrant further investigation in head and neck radiotherapy.

A number of techniques to account for organ motion in the delivery of
radiotherapy have been proposed but not widely adopted[5].

This lack of

adoption may be due to the difficulty is assessing the effectiveness or otherwise
of these devices. The analysis techniques used in chapter 4 were suited perfectly
to investigating the organ motion problem on delineated daily CBCT imaging
and could be applied to a number of situations to assess the effectiveness of
IGRT approaches.

Clinical trials are regarded as the gold standard when it comes to making
informed decisions about health care interventions[6]. However, it is also
recognised that clinical trials need to be robustly designed and implemented to
ensure results are unbiased[6]. Quality assurance in radiotherapy clinical trials is
the key tool in ensuring that the results of a trial are valid and widely applicable.
By assessing the impact of contouring variation on modelled outcome using the
same analysis techniques described in chapter 4 it is possible to make clinical
trials more robust to radiotherapy planning uncertainty, thus increasing the
effectiveness and impact of these trials which form the cornerstone of
radiotherapy practice.
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This thesis represents a body of work investigating areas of uncertainty in
radiotherapy planning, delivery and clinical trials. The main themes of the
conducted research were outlined in Chapter 1 and include:

I.
II.
III.

The impact of contouring variation on modelled radiotherapy outcome
The influence of planner experience on IMRT plan quality
Investigation of organ stability, dosimetry, and margins in the presence
of organ stabilising devices

IV.

Benchmarking and assessing the impact of contouring variation in
radiotherapy clinical trials

Like William Tell, guiding the arrow to hit the apple, the delivery of safe and
effective radiotherapy needs to be both accurate and precise. Accuracy and
precision are inextricably linked in the aim of radiotherapy; to maximise the
probability of cure without injury. The work presented here seeks to address
the issue of precision. The issue of accuracy can only be addressed once
radiotherapy contouring, planning and treatment are precise.

10.2 The impact of contouring variation on modelled
radiotherapy outcome
Chapter 4 investigated the relationship between geometric contouring variation
and outcome surrogates in the form of tumour control probability (TCP),
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equivalent uniform dose (EUD) and mean lung dose, for a series of non-small
cell lung cancer (NSCLC) patients. With a view to recommend relevant
geometric parameters for the assessment of contouring variation that relate to
modelled clinical outcome. Seven patients were included in the study and
contouring was performed by three observers on CT and PET imaging datasets.
Geometric variation was assessed and compared to resulting variation in TCP,
EUD and mean lung dose.

Statistically significant relationships were observed for most geometric
parameters with the strongest correlation pertaining to medial-lateral
dimension of the target volume, centre of mass, and concordance index. In
Chapter 3 it was found that medial-lateral dimension was employed in only
1/10 of the lung studies reviewed, while centre of mass and concordance index
were used in 4/10 and 2/10, and volume was the metric of choice in 8/10
studies. This highlights that the choice of metric for assessment of contouring
variation is not driven by relevance to clinical outcome but likely by the tools
available to investigators. The results of this work should inform the choice of
metric used and ensure future contouring studies are more consistent and
comparable.

Most investigations of contouring variation require some sort of reference
volume to compare to. This is often called the ‘gold standard’ or ‘reference’
volume. As the true extent of the tumour is not known these gold standard

______________________________________________________________________________________________________________________
178

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

volumes can take a number of forms; mathematical averages, probabilistic (e.g.
STAPLE), consensus, and most experienced observer, have all been used in the
literature. This is an area that warrants further investigation as the choice of
gold standard can have a strong influence on the analysis of results.
Understanding the impact of the choice of gold standard on the typical
contouring variation metrics is of interest. This, in conjunction with the impact
on dosimetry, may also serve to provide some reference values for typical
contouring variation metrics for future investigators.

10.3 The influence of planner experience on IMRT plan
quality
In Chapter 5, the impact of varying degrees of radiotherapy planner experience
on plan quality was presented. Six planners generated IMRT treatment plans for
a T2N3M0 tonsilar carcinoma case according to department protocol. Plans were
compared visually by an experienced radiation oncologist and also using a
number of dose-volume constraints and conformity indices. Delivery efficiency
and dose accuracy were also compared. Only 3/6 of the planners were able to
meet the dose objectives for the PTV. All planners could meet the constraints for
the brainstem, spinal cord, mandible and oral cavity, with the exception of one
planner whom failed to meet the mandible constraint. No planners achieved the
required dose volume constraints for the right parotid or larynx but these
structures overlapped with the PTV. Interestingly, the radiation oncologist, on
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slice by slice review, deemed all plans of a clinically acceptable quality.
Treatment delivery time and monitor units ranged from 15-25 minutes and just
under 800 to over 1200 MU with delivery time increasing with decreasing
planner experience. The planner with the least experience had the poorest plan,
as indicated by meeting the fewest PTV constraints.

10.4 Investigation of organ stability, dosimetry, and margins
in the presence of organ stabilising devices
An investigation into the use of ERBs in the post prostatectomy setting is
presented in Chapters 6 and 7. It has been known for some time that the
prostate bed can experience inter- and intra-fraction motion due its proximity
to the bladder and bowel, organs that are constantly filling and emptying[7]. This
study was completed in two parts. The first of which, Chapter 6, addressed the
question of whether the addition of an ERB in situ improved dosimetric interfraction reproducibility with the same treatment margins. The second, Chapter
7, investigated whether the organ motion component of the PTV margin could
be reduced when an ERB is used. For both of these studies 20 patients were
included in the investigation, 10 retrospective patients treated with standard
practice and 10 prospective patients treated with an ERB in situ. The treatment
consisted of IMRT with a prescribed dose of 70 Gy to the inferior CTV and 64.4
Gy to the superior CTV.
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The ERB significantly improved inter-fraction reproducibility for the rectum
and the CTV. Concordance indices for non-ERB and ERB of 0.50 ± 0.12/0.71 ±
0.07 for the rectum and 0.72 ± 0.15/0.73 ± 0.11 for the CTV. However, the
improved geometric stability with the ERB did not translate into a statistically
significant benefit in inter-fraction dosimetric stability based on a change in
equivalent uniform dose (ΔEUD). A reduced dosimetric stability for the bladder
and supCTV was found and is likely due to bladder filling and slight differences
in ERB insertion depth between fractions. One of the positive aspects of using
the ERB was that it reduced the impact of bladder filling on CTV stability. The
results of Chapter 6 agree with previous investigations in that a differential PTV
margin is warranted given the relative difference in stability between the
superior and inferior CTV.

10.5 Benchmarking and assessing the impact of contouring
variation in radiotherapy clinical trials
Radiotherapy clinical trial quality assurance has become a focus in recent times,
due in part to some sobering secondary analyses[8, 9] of large, well-funded and
run cooperative group run trials. Chapters 8 and 9 illustrate the implementation
of a dummy run to assess any possible protocol non-compliance and a
modelling study incorporating the results of the dummy run into the trial
design. While it is well understood that uncertainty due to contouring variation
is larger than that of setup error for some tumour sites[1], hence the routine use
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of dummy run exercises, there has been no effort to account for this in the
design of clinical trials.

The range of variation in volume was 228.5-497.8 cm3 for CTV contouring.
Uncertainty was largest in the z (superior / inferior) direction where
investigators did not adhere to protocol contouring guidelines. For the
benchmarking study the dose from the investigator submitted plans were
analysed against a set of gold standard contours. Dosimetric variation in
Chapter 8 was not substantial, although it should be noted that the four field
(4FLD) box planning technique used is relatively insensitive to contouring
variation within the borders of the “box” dose distribution. In Chapter 9, to
remove variation due to planning and focus on contouring all planning was
performed centrally using a class solution planning technique. The IMRT
planning technique demonstrated the largest variation in TCP with a range of
0.65-0.68, due to the conformity of the dose distribution with the shape of the
contour. This TCP variation did not have a large impact on the required sample
size, only requiring an extra 19 patients for the worst case. However this work
provides a framework to incorporate uncertainties quantified as part of routine
dummy run exercises to ensure robust results are obtained from RCTs.
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10.6 Future work
From the topics presented in this thesis there are a number of issues that justify
further investigation, including:
I.

The introduction of guidelines and minimum reporting requirements for
the conduct of contouring studies in radiation oncology

II.

Applying the technique presented in Chapter 4 to other treatment sites
to determine the appropriate metrics of contour variation to report.

III.

The intra-fraction stability of the post prostatectomy target volume with
ERB in situ

IV.

The development of automated methods of performing radiotherapy
clinical trial quality assurance

V.

The inclusion of planning and delivery uncertainties in prospective
radiotherapy clinical trials

As outlined in Chapter 3 there is no consistent evidence based method of
contour comparison within the literature. Contouring uncertainty has become
increasingly important as the accuracy of dose calculation and radiation
delivery has improved. Without a consistent method of reporting variation in
contouring for tumour sites, it will continue to be problematic to combine the
results of these studies in meta-analyses. There has been a push from some
publishers to include a minimum set of information when reporting planning
studies so that other investigators can repeat experiments and compare
hypotheses, the same should apply to contouring studies[10]. A review or
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recommendation publication detailing appropriate methodology and reporting
for contouring studies would facilitate the comparison of results from different
studies and allow for the appraisal of the quality of individual studies in a
uniform way. Applying the work presented in Chapter 4 to other treatment sites
and techniques will inform the appropriate contouring variation metrics to use.

Further investigation is warranted by extending the studies presented in
Chapters 6 and 7, including a larger number of patients and analysing intrafraction motion. The pilot study presented in Chapter 6 could be used to inform
the sample size calculation for a larger prospective trial. As part of that trial the
impact of the ERB on intra-fraction motion should also be considered. Although
SBRT has not been used in the post-prostatectomy setting to date, a thorough
understanding of intra-fraction motion is needed perform SBRT safely.

Radiotherapy clinical trials are expensive, time consuming and complicated to
run[6]. It is therefore important that the methods used when conducting a trial
are robust and the protocol strictly adhered to. The technique presented in
Chapter 9 could be used in prospective clinical trials to ensure there is adequate
statistical power in the design of the trial to account for treatment uncertainties.
Expert review is the current method of individual case review in radiotherapy
trials. This is very expensive and can be a limiting factor to recruitment in some
instances. Moreover, for trials involving adaptive radiotherapy where a patient
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may have many treatment plans that require review, manual expert review will
not be viable.

10.7 Summary
This work assessed the impact of organ motion, planner experience and
contouring variation on plan quality. Furthermore, the same techniques were
applied to a clinical trial dummy run, the results of which were used to assess
the impact of contouring variation on the statistical power of an RCT. A method
to ascertain the most relevant metrics of use when assessing contouring
variation was presented. The choice of such metrics will be site and planning
technique specific. Planner experience was demonstrated to have an impact on
the quality of radiotherapy planning for head and neck IMRT. A lack of planning
experience also resulted in IMRT plans that were less efficient to deliver. It was
shown that the ERBs reduce the amount of inter-fraction motion for post
prostatectomy radiotherapy. However, a larger prospective trial is required to
confirm these results and the dosimetric impact of the ERB. A technique for the
incorporation of planning uncertainty into clinical trial sample size calculations
was proposed. This process, combined with rigorous QA, provides a simple
means to use data from dummy run exercises to ensure the robustness of the
trial sample size calculations.
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This dissertation represents a series of studies into the impact on radiotherapy
quality and clinical trial power of organ motion, planner experience and
contouring variation. The key priorities for continuing this work are:


Developing standardised practices when performing and reporting
contouring studies in radiation oncology



Using the results of benchmarking procedures to ensure the robustness
of sample size calculations in RCTs

It is hoped the work reported in this thesis will contribute to the way in which
clinician defined contour uncertainties, organ motion uncertainties and there
impact on dose targeting and hence tumour control are assessed and reported
in the future.
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Appendix A: A phantom assessment of achievable contouring
concordance across multiple treatment planning systems
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a b s t r a c t
In this paper, the highest level of inter- and intra-observer conformity achievable with different
treatment planning systems (TPSs), contouring tools, shapes, and sites have been established for metrics
including the Dice similarity coefficient (DICE) and Hausdorff Distance. High conformity values,
e.g. DICEBreast_Shape = 0.99 ± 0.01, were achieved. Decreasing image resolution decreased contouring
conformity.
Ó 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2015) xxx–xxx

Delineation of radiotherapy structures has direct clinical consequences. Contouring of nodal CTV sub-volumes in particular, is
critical [1]. Even moderate geometrical differences in small neck
Planning Target Volumes (PTVs) can impact on the target dose
(up to 11 Gy reductions in D99 for DICE above 0.8) [2]. For
non-small lung cancer variation a concordance index (CI) has been
demonstrated to result in variation in Tumour Control Probability
(TCP) [3], highlighting the correlation between contour variation
and TCP. However, there are no reported contour variation metric
baseline values considering uncertainties in the process such as
different treatment planning systems (TPSs), importing and
exporting processes, contour shapes, volumes and image resolution. Knowledge of these baseline values is important for clinical
trials which commonly occur across multiple centres and TPSs.
Current literature does not give clear guidelines for reporting
contouring variability in inter-observer studies [4] with variation
in methodology and metrics only enabling comparison between
inter-observer studies in a limited fashion [5]. As such, calculating
multiple metrics including a combination of descriptive statistics,

⇑ Corresponding author at: School of Physics, Engineering and Information
Sciences, University of Wollongong, Wollongong, NSW 2522, Australia.
E-mail address: elisep@uow.edu.au (E.M. Pogson).

overlap measures and statistical measures of agreement is
recommended for multiple observer studies [6].
The number of studies reporting on auto-segmentation [7,8],
and the inter- [9,10] and intra- [11] observer conformity of
volumes is growing. Inadequate definition of the Gross Tumour
Volume (GTV) or Clinical Target Volume (CTV) leads to systematic
uncertainty which may result in geometric miss of the tumour
throughout the course of patient radiation therapy [5]. As such
there has been an increasing trend to assess, and reduce, the variability of these target volumes. This study determined the highest
concordance metrics achievable, and how these metrics (details
given in Supplementary Table 1) may vary in a best case phantom
scenario considering: multiple sites, variation between TPSs,
shapes, volume, tools utilized and adherence to auto-threshold
settings within the protocol.

Methods
A Quasar Body phantom (Modus Medical Devices Incorporated,
Ontario Canada) was used to provide an initial CT dataset. The
Quasar phantom was scanned on a Brilliance Big Bore CT (Phillips
Healthcare, The Netherlands) using a helical abdomen scanning
sequence: 1 mm slice spacing, 2 mm slice thickness, standard

http://dx.doi.org/10.1016/j.radonc.2015.09.022
0167-8140/Ó 2015 Elsevier Ireland Ltd. All rights reserved.
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resolution (512  512) and field of view of 350 mm. This phantom
had three inserts containing structures providing a range of surface
contours and edges. In this study the 20-degree air wedge contained in the first insert (referred to as the triangular prism) and
the entire empty third insert (an 8 cm diameter cylinder with
semi-conic top) were used for contouring.
The Quasar phantom CT dataset was imported into MATLAB
R2012a (Mathworks Incorporated, Natick USA). Uniform rectangular prisms and a patient breast volume (203 cm3) were inserted
into the CT dataset using ‘Computational Environment for Radiotherapy Research’ (CERR) [12,13] and MATLAB. High intensities
were utilized to obtain optimal image contrast. The Quasar
phantom with inserted shapes is displayed, with inter-observer
contours, in Supplementary Fig. 1.
A contouring protocol set image window levels to Window/
Level = 400/800 HU and described allowable techniques/tools. All
eight rectangular prisms were auto-contoured using autothreshold at recommended threshold values or other automated
tools (e.g. Oncentra’s magic-wand tool). Rectangular prisms 1, 4
and 8 (Supplementary Fig. 1) were manually contoured. Bounding
boxes in auto-contouring and zoom functions were allowed. The
breast contour was manually delineated; allowing interpolation
between slices and/or copy to next slice. The triangular prism
and cylinder were both delineated using automated tools (such
as auto-threshold) and manually. All eight observers were blind
to others contours. The TPSs used for contouring were; Eclipse
Planning System 11.0.64 (Varian Medical Systems, Palo Alto
Canada): two sites, Oncentra (Elekta, Stockholm Sweden): two
sites, Pinnacle3 9.0 (Philips, Netherlands): two sites, and FocalSim
4.80.01 (Elekta, Stockholm Sweden): two sites. These contours
were then exported and collated in CERR.
The same original 512  512 data-set was contoured five times
by four observers, with a minimal 24 h time lapse between contouring. Pairwise analysis of the Jaccard Index (JI) also known as
conformity index or concordance index (CI) [6,14] (CIpairs the average of all possible pairs of the JI which equates to CIgen when
mutual variability between all observers is the same [15]), Volume
Overlap Index (VOI) and Hausdorff Distances (HDs) were calculated for each observer and averaged. This was performed for all
manually contoured structures.
Different studies have different image resolutions. As such the
Quasar phantom was resampled and contoured by five different
observers, to show the expected inter-observer effects for differing
sample/dataset pixel size and slice thickness. The resampling was
performed in MATLAB with the overall volume maintained. Slice
thickness was also set to the spacing of 2 mm, 4 mm and 8 mm
keeping the resolution at 512  512 px (1.463 px/mm) and saved
as DICOM. The resampled DICOM data were of the following resolutions; 512  512 px2 (1.463 px/mm – a typical high resolution
CT), 350  350 px2 (1.000 px/mm), 245  245 px2 (0.700 px/mm),
175  175 px2 (0.500 px/mm), 88  88 px2 (0.250 px/mm), and
44  44 px2 (0.125 px/mm).
To allow comparison between observers, simultaneous truth
and performance level estimation (STAPLE) volumes were
generated as consensus gold standard reference volumes in CERR,
using a 90% confidence interval with observers weighted equally.
CERR was utilized to calculate the generalized kappa statistic as
well as the DICE, and JI in three dimensions for all observers
comparing to the gold standard STAPLE volume (Supplementary
Table 1). The maximal HD, average Hausdorff Distance, CIpairs and
VOI was calculated in a pairwise analysis over all volumes in
MilxView (Australian e-Health Research Centre (AEHRC), Australia)
[16,17] (Supplementary Table 2).
The JI [18–20], DICE [4], Hausdorff distance [21] and Kappa (j)
statistic [22,23] outlined in Supplementary Table 1, are metrics
commonly used to establish inter-observer variation [6]. JI and

DICE values from CERR were verified in 3D Slicer [24–26] and
MILXview and were consistent to within 2 significant figures.
Results
Eight auto-contoured, inter-observer rectangular prism
contours from different TPSs were all within two pixels of the true
volume on every slice, for every point within the contour (Fig. 1(a)).
The maximum HD of these contours compared to the STAPLE ranged from 1 pixel width/height (0.68 mm) or 2 pixels added in
quadrature (0.97 mm), with a maximum of 3 pixels (2.04 mm) for
the auto-contoured rectangular prisms (Fig. 1(c)). As the STAPLE
for square 5 is different to the true volume there are larger HDs
and discrepancies for this volume. A pairwise HD measure, rather
than to the STAPLE, is less sensitive to such errors and is used in
all following analysis. Fig. 1(b) displays each inter-observer’s DICE
compared to the STAPLE. Inter- and intra- observer contour variation as measured by maximum HD relative to the STAPLE volumes
was less than 7 mm for all volumes at normal resolution (1.463 px/
mm). Kappa statistics comparing multiple shapes from the Quasar
phantom show near perfect agreement for most shapes despite
asymmetry from the breast contour (Supplementary Fig. 2).
Auto-contoured rectangular prisms were less conformal
(kappa in the range of 0.61–0.80) than manually delineated shapes
(kappa in the range of 0.81–1), (Supplementary Fig. 2), with other
shapes having no difference. The contouring tool used did not
show any observable effect in contour conformity. Average manual
and auto-threshold DICE were in agreement (within the 95%

Fig. 1. Auto-contoured squares; a) Percentage deviation of volume from the true
volume. Majority of contours are within 1 px and the rest within 2 px, b) DICE c)
maximum HD from the STAPLE volume.
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confidence limit) for all shapes. The JI, average DICE and kappa for
the manually delineated shapes are summarized in Supplementary
Table 2.
Inter-observer generalized kappa statistics for differing shapes
is shown in Fig. 2(a). Decreasing image resolution reduces concordance, especially for smaller structure volumes e.g. triangular
prism (47 cm3). This is evident in the average DICE compared to
the STAPLE volume in each image (Fig. 2(b)) and the average
maximal HDs (Fig. 2(c)). The breast contour and some rectangular
prisms with an image resolution of 0.250 px/mm and 0.125 px/mm
were excluded as the outline was not visible at recommended
window levels due to resampling.
As resolution decreases below 0.250 px/mm, the relative interobserver DICE also decreases for manual contours, despite Fig. 2(b)
showing good concordance compared to the STAPLE generated on
each individual resolution dataset. Supplementary Fig. 3, displays
the relative DICE of contours with lowering resolution compared
to the highest resolution image (1.49).
Varying the slice thickness from 1 mm to 2 mm, 4 mm and
8 mm had no significant effect on inter-observer conformity.
Discussion
This investigation has demonstrated that despite the use of
multiple treatment planning systems, it is possible to achieve close
to perfect conformity between observers with a high contrast dataset. Conformity is reduced with reduction in image resolution and
volume of the structure considered.
The relative deviation, as shown in Fig. 1, increases for smaller
volumes i.e. up to 30% for a small volume of 2.7 cm3. Additional
differences may occur during import and export through multiple
TPSs, as the same volume exported from multiple TPSs has been
shown to vary from 2% to 4% for small volumes (less than
250 cc) [27]. The HDs, as shown in Fig. 2(c), are increasing due to
lengthening pixel sizes. This was similar to results shown in
another study [28].
Inter-observer variation is shown to increase with lower resolution. Intra-observer variation is either in agreement or smaller than
inter-observer variation similarly to previously reported clinical
findings [5]. Disagreement between the same TPS is evident for
contours generated using auto-threshold tools in the same TPS
by different observers, (Fig. 1(c)). Hounsfield Units (HUs) used for
Auto-thresholding were requested, and showed significantly
different HUs had been used. This ambiguity is likely due to conversion between TPSs. We recommend that the conversion
between multiple TPSs for inter-observer studies be performed
and sent out with the study dataset in future studies. The highest
achievable values are dependent upon image resolution, contour
volume, number of observers, image contrast, window level and
adherence to the protocol.
Previously reported values in breast radiotherapy CTV interobserver studies include a JI of; 0.81 for radiation oncologist breast
contouring [9], 0.84 for radiation therapist breast contouring [9],
0.87 for glandular breast volumes [14], 0.56 for partial breast
volumes [14] and 0.82 for glioblastoma GTV’s (Gross Tumour
Volumes) [29]. An inter-observer breast contour generalized kappa
of 0.97 (p < 0.05), maximal HD of 3.42 mm, average JI of 0.98 ± 0.01
and average DICE of 0.99 ± 0.01 was found in this study. This
demonstrates the highest achievable values for future expert clinician contours compared to a STAPLE volume, for an acceptable
number of observers (five or more, with a recommendation to have
as large a number of expert observers as possible for small volumes
[28]) and a standard CT image resolution (512  512). The gold
standard STAPLE volume has been generated by the contours
assessed here, whilst this has minimal effect, in an ideal study
the aim would be to have a separate group of contours to generate

Fig. 2. Manually delineated Inter-observer a) STAPLE parameters with differing
image resolution; Kappa, Specificity, Sensitivity and Volume, b) 5 observer average
DICE and c) 5 observer average Hausdorff Distances. Error bars represent 1SD. The
STAPLE in the resampled images have lower specificity and sensitivity with
lowering resolution. The 95% confidence intervals also increase, for small volumes,
with worsening resolution (as the amount of data is reduced).

a gold standard STAPLE and compare to this. To avoid this metrics
such as CIpairs or VOI may be utilized instead. Complexity of shape
showed no observable effect in conformity, as the complicated
breast contour achieved a higher average DICE, average JI and
Kappa than the cylinder and rectangular prism, of similar volumes.
However an assessment of more complicated irregular shapes than
rounded breast contours still needs to be undertaken.
In summary, multi-observer results from multiple TPSs, differing TPS tools, image resolution, image slice thickness, contour
shapes and volumes has been established for average DICE, average
JI, CIpairs, VOI, kappa, average HD and maximum HD. Values
obtained in this phantom study suggest that multiple sites and systems do not have significant impact on concordance metrics for
these particular volumes. Values presented here may provide an
upper bound as to what is achievable in future studies. Alternatively if images are of significantly different image resolution,
extremely small volumes (such as a head and neck study), of more
irregular shape, or with less observers, future studies might consider including another object/dataset to determine their highest
achievable kappa, average DICE or average JI under these circumstances. This could be undertaken on a study by study basis.
Disclaimer
The views expressed in this article are my own and not an
official position of the institution or funding support.
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Appendix B: Contouring Variability and its Effect on
Radiobiology Parameters for Head and Neck Cancer
Yvette Griffiths, MSc, Sydney University, School of Physics
Supervisors: Dr Lois Holloway, Michael Jameson
Abstract
Inter and Intraobserver variation in delineation (or contouring) of tumour and normal
structures is a widely recognised issue in radiotherapy. Many studies have quantified
this variation and investigated ways to reduce it. If a contour is inaccurately delineated,
the tumour may be underdosed or normal tissues overdosed. Currently there are
studies that have shown a clinical impact from inter/intra observer variation through
the use of radiobiological models for both tumour and normal tissues.
The aim of this project is to investigate a potential correlation between geometrical
variations in contouring and radiobiologically modelled clinical outcome.
Multiple contours were generated mathematically and by observers on head and neck
cancer CT datasets. An IMRT dose distribution was generated based on each contour.
Then the contours were analysed for geometric variation and modeled clinical outcome.
The contouring variation and modelled clinical outcome was correlated.
The results showed a 13.86% length variation in the x direction, as a percentage of the
mean. The change in predicted clinical outcome was 56.68% (of the mean). A trend in
correlation was seen between the length of the x, y and z dimensions and modelled
clinical outcome. A trend was also seen between volume change and predicted clinical
outcome.
The correlation trends found in this study could potentially be used for predicting the
effect that contouring change clinical outcome. To achieve more conclusive results, a
larger future study would be required, in order to develop guidelines to predict the
effect of inaccurate structure delineation.
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